Polyvinylamides for flocculation of antibodies
Patent Information
- Application Number
- PCT/EP2026/061884
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-04-24
- Publication Date
- 2026-11-12
Smart Images

Figure EP2026061884_12112026_PF_FP_ABST
Abstract
Description
[0001] Polyvinylamides for flocculation of antibodies
[0002] Technical Field
[0003] The present invention relates to the field of manufacturing and purification of biopharmaceuticals. Specifically, the present invention relates to a method for purifying an antibody or fragment thereof from an antibody secreting cell culture, comprising at least the following steps: a) treating the cell culture with (i) a partially hydrolyzed poly (N-vinyla- mide) according to formula I or a salt thereof,
[0004] n
[0005]
[0006] NRXR.|
[0007] formula I
[0008] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl;
[0009] (ii) a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof:
[0010]
[0011] formula IV,
[0012] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; and wherein the sum of R1 = H, COR2 and R3 is 100%; or
[0013] (iii) a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof
[0014]
[0015] formula V,
[0016] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00001 mol-% of the monomer units R1 = R3 = a label, in particular a fluorescent label.and b) separating the cell culture into a precipitate / solid and a supernatant / liquid fraction. Further, the invention, contemplates an antibody or fragment thereof obtained by or obtainable by said method and a composition comprising the antibody or fragment thereof and use of the partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof; of a mixture of the partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof; or of the labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof for antibody purification.
[0017] Background art
[0018] Manufacturing of biopharmaceuticals and therapeutic proteins is an expensive and time consuming endeavor. Demand for greater quantities of biopharmaceuticals and therapeutic recombinant proteins has driven advances in cell culture processing which have resulted in dramatically increased product titer. High titer cell culture processes are typically produced by maintaining high viable cell densities over longer culture durations. A corresponding increase in the biomass and cellular debris in the micron and submicron range are observed. The higher burden of solids and cellular debris may increase contamination with undesired host proteins and often negatively impacts cell culture harvest processes, making the harvest process less effective at removing the debris without a substantial loss of product. The processing and purification of antibodies from cell cultures requires numerous harvesting and purification steps, including chromatography and filtration. Nevertheless, co-purifying host cell proteins is often difficult to avoid. Still co-purified host cell proteins are undesired and may even encompass health risks for patients. In particular, so called high risk host cell proteins may interfere with downstream processes and / or downstream applications including therapeutic applications.
[0019] Different approaches have been reported aiming at increasing the yield and, more importantly, the purity of biopharmaceuticals recovered from cell cultures. One common strategy for improving product quality and purity when producing biopharmaceuticals in cell culture comprises the use of flocculating agents as a primary separation step. Patent applications US20180265542 and US20170240591 disclose using ligand functionalized polymers for flocculating a biological sample. Common flocculants that are used for flocculation in biopharmaceutical fermentation processes are polyethylenimine (PEI) and poly (diallyldimethylammonium chloride) (PDADMAC) as disclosed for example in WO 2014 / 118220 A1. Further, Gomez et al. Biochemical Engineering Journal 132 (2018) 244-254 report on flocculation in OHO cell culture for separating recombinant glycoproteins including monoclonal antibodies. Ma et al. Journal of Chromatography B 878 (2010) 798-806 report on using polyamines for flocculating antibody producing OHO cell culture. However, removal of high risk host cell proteins does not appear to be addressed sufficiently in the prior art and remains at an undesired level.
[0020] Problem to be solvedThere is hence a continuing need for improving cell culture harvest methods and methods for purifying cell-culture derived biopharmaceuticals, particularly methods for harvesting or purifying antibodies or antibody fragments. Any improvements that allow for quicker recovery times and / or greater recovery can lead to reduced costs associated with manufacturing. Therefore, it is desired to simplify the purification steps while maintaining high product yield and ensuring or even improving high product quality requirements. In particular, there is a need for reducing levels of copurified high risk host cell proteins, more particularly there is a need for reducing levels of co-purified high risk host cell proteins from all types of host cell cultures, e.g. mammalian and microbial cell cultures.
[0021] Summary
[0022] The technical problem underlying the present invention may be regarded as the provision of means and methods for complying with the aforementioned needs.
[0023] This problem is addressed by a method and use with the features of the independent claims. Advantageous embodiments which might be realized in an isolated fashion or in any arbitrary combinations are listed in the dependent claims as well as throughout the specification.
[0024] Accordingly, the present invention relates to a method for purifying an antibody or fragment thereof, comprising at least the following steps: a) treating the cell culture with a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof:
[0025]
[0026] formula I
[0027] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and b) separating the cell culture into a precipitate / solid and a supernatant / liquid fraction. Typically, the sum of R1 = H and R1 = COR2 is 100 %.
[0028] Advantageously, it has been found in accordance with the present invention that the purification method for an antibody and / or fragment thereof making use of said partially hydrolyzed poly (N-vinylamide) according to formula I results in improved removal of undesired host cell contaminants including DNA and host cell proteins from an antibody secreting cell culture. In particular, the amount of so-called high risk host cell proteins that may be co-purified with the antibody or fragment thereof is significantly reduced. Moreover, the method according to the invention provides excellent clarification and purification of the antibody or fragment thereof without impacting yield.Moreover, the present invention relates to a method for purifying an antibody or fragment thereof, comprising at least the following steps: a) treating the cell culture with a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof
[0029]
[0030] formula IV,
[0031] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; or
[0032] a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof
[0033]
[0034] NRXR1
[0035] formula V,
[0036] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label;
[0037] and
[0038] b) separating the cell culture into a precipitate / solid and a supernatant / liquid fraction. Typically, the sum of R1 = H and R1 = COR2 and R1 = R3 = a label is 100 %.
[0039] Using a labeled partially hydrolyzed poly (N-vinylamide) or a mixture comprising the same, typically has the above mentioned advantages of leading to improved removal of undesired host cell contaminants including DNA and host cell proteins from an anti-body secreting cell culture. In particular, the amount of so-called high risk host cell proteins that may be co-purified with the antibody or fragment thereof is significantly reduced. Moreover, the method according to the invention provides excellent clarification and purification of the antibody or fragment thereof without impacting yield. However, the labeled partially hydrolyzed poly (N-vinylamide) or a mixture comprising the same has the additional advantage of offering the possibility of efficient, simple and immediate detection of any residual labeled partially hydrolyzed poly (N-vinylamide) - by itself or as a kind of indicator for residual unlabeled partially hydrolyzed poly (N-vinyla-mide) - after purification, thereby reducing analytical efforts required for ensuring antibody purity.It is to be understood that this invention is not limited to the particular methodology, protocols, reagents etc. described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention that will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
[0040] It is to be understood that as used in the specification and in the claims, "a” or "an” can mean one or more, depending upon the context in which it is used. Thus, for example, reference to "a host cell” can mean that at least one host cell can be utilized.
[0041] As used herein, the terms "have”, "comprise” or "include” or any arbitrary grammatical variations thereof are used in a non-exclusive way. Thus, these terms may both refer to a situation in which, besides the feature introduced by these terms, no further features are present in the entity described in this context and to a situation in which one or more further features are present. As an example, the expressions "A has B”, "A comprises B” and "A includes B” may both refer to a situation in which, besides B, no other element is present in A (i.e. a situation in which A solely and exclusively consists of B) and to a situation in which, besides B, one or more further elements are present in entity A, such as element C, elements C and D or even further elements.
[0042] Further, it shall be noted that the terms "at least one”, "one or more” or similar expressions indicating that a feature or element may be present once or more than once typically are used only once when introducing the respective feature or element. In most cases, when referring to the respective feature or element, the expressions "at least one” or "one or more” are not repeated, notwithstanding the fact that the respective feature or element may be present once or more than once.
[0043] The term "about” as used herein means that with respect to any number recited after said term an interval accuracy exists within in which a technical effect can be achieved. Accordingly, about as referred to herein, preferably, refers to the precise numerical value or a range around said precise numerical value of ±20 %, preferably ±15 %, more preferably ±10 %, or even more preferably ±5 %.
[0044] Further, as used herein, the terms "preferably", "more preferably", "particularly", "more particularly", "specifically", "more specifically" or similar terms are used in conjunction with optional features, without restricting alternative possibilities. Thus, features introduced by these terms are optional features and are not intended to restrict the scope of the claims in any way. The invention may, as the skilled person will recognize, be performed by using alternative features. Similarly, features introduced by "in an embodiment of the invention" or similar expressions are intended to be optional features, without any restriction regarding alternative embodiments of the invention, without any restrictions regarding the scope of the invention and without any restriction regarding the possibility of combining the features introduced in such way with other optional or non-optional features of the invention.The term "antibody or fragment thereof” as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art and is not to be limited to a special or customized meaning. The term "antibody” specifically may refer, without limitation, to immunoglobulins or immunoglobulin-like molecules. The term specifically includes by way of example and without limitation, IgA, IgD, IgE, IgG and IgM, combinations thereof, and similar molecules produced during an immune response in any vertebrate, for example, in mammals such as goats, rabbits and mice, as well as non-mammalian species, such as shark immunoglobulins. The term more specifically, includes synthetic antibodies, monoclonal antibodies, recombinantly produced antibodies, multi-specific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, murine antibodies, chimeric antibodies, and intrabodies. The term hence, typically, refers to all classes of antibodies such as described by V. Bayer in Seminars in Oncology Nursing 35 (2019) 150927.
[0045] In particular, antibodies and fragments thereof include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., antigen binding domains or molecules that contain an antigen-binding site that specifically binds to the antigen (e.g., six complementarity determining regions (CDRs) of an antibody). The antibodies can be of any class (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), any subclass (e.g., lgG1, lgG2, lgG3, lgG4, lgA1, and lgA2), or any subclass (e.g., lgG2a and lgG2b) of immunoglobulin molecule. Typically, the antibody is a humanized antibody or a human antibody. More typically, the antibody is an IgG antibody.
[0046] The term "antibody fragment” as used herein specifically refers to a portion of an intact antibody, more specifically to a portion comprising the antigen-binding region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments; furthermore single-domain antibodies (also referred to as immunoglobulin single variable domain(ISVD), e.g. Nanobody® molecule), including monospecific, bispecific, multi-specific single-domain antibodies, single-chain Fvs (scFv) (e.g..including monospecific, bispecific, etc.), camelid antibodies, and fragments such as Fab fragments, F(ab')2 fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-ld) antibodies, and epitope-binding fragments of any of the above
[0047] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment of an antibody yields an F(ab')2 fragment that has two antigen-combining sites and is still capable of crosslinking antigen. "Fv” is the minimum antibody fragment which contains a complete antigen-binding site. Preferably, a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In a single-chain Fv (scFv) species, one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric” structure analogous to that in a two-chain Fv species. It is in this configuration that the three hypervariable regions (HVRs, also re-ferred to as complementarity determining regions (CDRs)) of each variable domain interact to define an antigen-binding site. Collectively, the six HVRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three HVRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site. The term "diabodies” refers to antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies may be bivalent or bispecific. Diabodies are described more fully in, for example, EP 0404097; WO 1993 / 01161; Hudson et al., Nat. Med. 9 (2003) 129-134; and Hollinger et al., PNAS USA 90 (1993) 6444-6448. Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9 (2003) 129-134.
[0048] The term "single-domain antibody" (VHH) or "nanobody", relates to an antibody fragment comprising one variable antibody domain and is, in principle, known to the skilled person. A review is provided, e.g. in Muyldermanns et al. (2009), Vet Immunol Immunopathol. 128(1-3):178.
[0049] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of essentially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the modifier "monoclonal” indicates the character of the antibody as not being a mixture of discrete antibodies. As used herein, the term "monoclonal antibody” refers to an antibody produced by a single clone of B-lymphocytes or by a cell into which the light and heavy chain genes of a single antibody have been transfected. Monoclonal antibodies are produced by methods known to those of skill in the art, for instance by making hybrid antibody-forming cells from a fusion of myeloma cells with immune spleen cells.
[0050] The term "antibody” may also encompass mixtures of antibodies, such as a mixture of two antibodies or more.
[0051] The antibody may be a therapeutic antibody, i.e. an antibody in use in therapy. Further, the antibody may be a monoclonal antibody. In particular, the antibody or fragment thereof may be a human or humanized antibody or fragment thereof, more particularly a human or humanized monoclonal antibody.
[0052] For example, according to the present invention, the antibody may typically be a murine antibody, like catumaxomab, blinatumomab, capromab, moxetumomab pasudotox-tdfk, muromonab-CD3; a chimeric antibody, like infliximab, cetuximab, siltuximab, rituximab; a humanized antibody, like atezolizumab, elotuzumab, pembrolizumab, eculizumab, fremanezumab-vfrm, omalizumab, galcanezumab-gnlm, palivizumab, monalizumab, mepolizumab, trastuzumab, obinutuzumab, ocrelizumab, pertuzumab, vedolizumab, tocilizumab, bevacizumab, alemtuzumab, certolizumab (pegol) and benralizumab; or a human antibody, like adalimumab, anti-Spike (ICO-hu104, anti-SARS-CoV2 Wuhanstrain S1 protein), belimumab, evolocumab, nivolumab, durvalumab, ofatumumab, panitumumab, daratumumab, denosumab, golimumab, avelumab ramucirumab, secukinumab, olaratumab, necitumumab, guselkumab, usteki-numab, orcNISTmAb.
[0053] For example, the antibody may be selected from the group consisting of atezolizumab, elotuzumab, pembrolizumab, eculizumab, fremanezumab-vfrm, omalizumab, galcanezumab-gnlm, palivizumab, monalizumab, mepolizumab, trastuzumab, obinutuzumab, ocrelizumab, pertuzumab, vedolizumab, tocilizumab, bevacizumab, alemtuzumab, cer-tolizumab (pegol) and benralizumab; adalimumab, anti-Spike (ICO-hu104, anti-SARS-CoV2 Wuhan strain S1 protein), belimumab, evolocumab, nivolumab, durvalumab, ofatumumab, panitumumab, daratumumab, denosumab, golimumab, avelumab ramucirumab, secukinumab, olaratumab, necitumumab, guselkumab, ustekinumab, and cNIST-mAb. Preferably the antibody is a human antibody or a humanized antibody. More preferably the antibody is selected from adalimumab, anti-Spike, cNISTmAb, and trastuzumab.
[0054] The term "purifying an antibody or fragment thereof” as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art and is not to be limited to a special or customized meaning. The term specifically may refer, without limitation, to a step "rendering said antibody or fragment thereof more pure". Hence, "purifying” refers to recovering an antibody or fragment thereof, typically it involves separating an antibody or fragment thereof from other compounds present in a cell culture, in particular separating the antibody or fragment thereof from the solid fraction of the cell culture, more particularly "purifying an antibody or fragment thereof” may comprise the steps of the method according to the invention as described herein in more detail.
[0055] The term "antibody secreting cell culture” as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art and is not to be limited to a special or customized meaning. The term specifically may refer, without limitation, to any type of cell culture capable of producing and secreting an antibody or fragment thereof. A "cell culture” as referred to herein relates to a plurality of cells of the same type that are cultivated in a suitable cultivation medium. Hence, the term "cell culture” may refer to said cells and said cultivation medium Similarly, the term "cell culture cells” as used herein refers to the cells of said cell cultures. Said cells are typically referred to as host cells suitable for recombinantly expressing said antibody or fragment thereof. More typically, the host cells serve as a host for recombinant expression of a gene construct encoding for the antibody or fragment thereof. Host cells in line with the present invention include bacterial host cells including Gram-negative and -positive bacteria and eukaryotic host cells including yeasts and filamentous fungi, insect cell lines, and mammalian cells, wherein mammalian host cells are preferred. Gram-negative bacteria suitable as cell culture in line with the invention include cells of Escherichia coir, Proteus mirabilis, and Pseudomonas putidas,' gram-positive bacteria include for example Bacillus species such as Bacillus brevis, Bacillus licheniformis, Bacillus subtilis, Bacillus megaterium, Lactobacillus zeae / casei and Lactobacillus paracase, preferably Bacillus brevis, Bacillus subtilis, Bacillus megaterium, Lactobacillus zeae / casei and Lactobacillus paracase. Yeast cells suitable as cell culture in line with the invention include cells of Pichia pastoris, Saccharomyces cerevisiae, Hansenula polymorpha, Schizosaccharomycespombe (93, 94), Schwanniomyces occidentalis, Kluyveromyces lactis, and Yarrowia lipolytica. Cells of filamentous fungi suitable as cell culture in line with the invention include cells of the genera Trichoderma and Aspergillus for example A. awamori, A. nidulans, A. niger, A. oryzae, Trichoderma reesei. Insect cells lines suitable as cell culture in line with the invention include Sf-9 and Sf-21 of Spodoptera frugiperda, DS2 cells of Drosophila melanogaster, and High Five cells (BTI-TN-5B1 -4) of Trichopulsia ni. Mammalian cell lines suitable as cell culture in line with the invention include Chinese hamster ovary (CHO) cells, and lines derived thereof such as K1-, S- , GS-, DukX B11-, DG44-cell lines; Per.C6 cells, mouse myeloma NSO cells, baby hamster kidney (BHK) cells and the human embryonic kidney cell line HEK293.
[0056] In particular, the antibody secreting cell culture is a mammalian cell culture; still more particularly, a cell culture comprising Chinese ovary hamster (CHO) cells. In other words, the cell culture according to the invention typically comprises CHO cells producing and secreting an antibody or fragment thereof, more typically CHO cells producing and secreting a humanized or human antibody or fragment thereof.
[0057] However, the antibody secreting cell culture in line with the invention may alternatively be a microbial cell culture, in particular a bacterial cell culture such as a gram-negative bacterial cell culture including Escherichia coli cell culture or a gram-positive bacterial cell culture such as a Bacillus cell culture, e.g. a cell culture of Bacillus brevis, Bacillus licheniformis, Bacillus subtilis, Bacillus megaterium, Lactobacillus zeae / casei and Lactobacillus paracasei. More preferably a gram-negative bacterial cell culture including Escherichia coli cell culture.
[0058] The cells of the cell culture are antibody secreting cells, hence they have the capacity to secrete the antibody or fragment thereof into the cultivation medium.
[0059] In case of a microbial, in particular a bacterial, antibody secreting cell culture the method for purifying an antibody or fragment thereof from said microbial or bacterial antibody secreting cell culture may comprise an additional step of lysing the cells of the cell culture. Cell lysis may in particular be necessary in case of cell cultures exhibiting incomplete secretion of the antibody into the fermentation medium. Means and method of lysing microbial or bacterial cells are known in the art and include for example high pressure homogenization, ultrasonification, bead beating, osmotic shock, chemical lysis, e.g. with strong surfactants, and enzymatically lysis, e.g. with lysozyme, preferably high pressure homogenization.
[0060] The terms "cultivation medium” and "fermentation medium” are used interchangeably herein. A "cultivation medium” typically refers to a water-based solution containing one or more chemical compounds that can support the growth of cells, i.e. cell cultures. Any medium suitable for the culture of the particular host cell may be used.
[0061] The fermentation medium may be a minimal bacterial growth medium as described before, e.g., in WO 98 / 37179, or the fermentation medium may be a complex medium comprising complex nitrogen and / or carbon sources, whereinthe complex nitrogen source may be partially hydrolyzed as described in WO 2004 / 003216. Furthermore, the fermentation medium may contain a phosphate and / or carbonate source. Typically, the fermentation medium may be a chemically defined animal-derived component-free cell culture medium supplemented with amino acids, vitamins, salts, trace elements, and glucose.
[0062] Compounds which may optionally be included in the fermentation medium are chelating agents, such as citric acid, MGDA, NTA, or GLDA, and buffering agents such as mono- and dipotassium phosphate, calcium carbonate, and the like. Buffering agents preferably are added when dealing with processes without an external pH control. In addition, an antifoaming agent may be dosed prior to and / or during the fermentation process. Additionally, the fermentation media may be supplemented with albumines, like bovine serum albumin, growth factors or other proteins; for example to improve yield and / or to stabilize the purified product, e.g. the antibody or fragment thereof.
[0063] The term "shear protectant” as used herein typically refers to any agent or chemical compound known in the art suitable for reducing shear stress in an aqueous solution, specifically in a cell culture. Shear stress to cells in cell culture may typically arise from the turbulent environment of bioreactors. Shear stress may cause damage to cells. Shear protectants suitable for cell culture may hence be added typically for improving cell viability. Suitable shear protectants preferably include poloxamers, e.g. tri block-copolymers each being composed of a block of polypropylene oxide flanked on both sides with a polyethylene oxide block, more preferably poloxamer 188, e.g. Kolliphor P188 Cell Culture (BASF) or the like, wherein each polyethylene oxide block is composed of 75 to 85 ethylenoxide units and the polypropylene oxide block is composed by 25 to 30 propylene oxide units.
[0064] Furthermore, suitable shear protectants may include meroxapols, being tri block-copolymers each being composed of a block of polyethylene oxide flanked on both sides with a polypropylene oxide block; particularly suitable are meroxapols wherein each polypropylene oxide block is composed of 1 to 31 propylene oxide units and the polyethylene oxide block is composed of 13 to 173 ethylene oxide units. More particularly, meroxapols are suitable having a peak-molecular weight Mpbetween 1000 and 8000 g / mol and a polyethylenoxid-percentage between 55 and 95 weight-%.
[0065] The present invention may be useful for purifying an antibody or fragment thereof from any fermentation process or cultivation process, such as in industrial scale, i.e., at least 1,000 liters, more preferably at least 5,000 liters, even more preferably at least 50,000 liters; but the invention may also be useful for purifying an antibody or fragment thereof in smaller scale processes such as in production processes for personalized medicine or laboratory or pilot production processes, such as processes in a scale of 50 L up to 200 L.
[0066] Treating a cell culture with a partially hydrolyzed poly (N-vinylamide)
[0067] The method according to the invention comprises a step a) of treating a cell culture with a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof as defined elsewhere herein in more detail.The term "partially hydrolyzed poly (N-vinylamide)” as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art and is not to be limited to a special or customized meaning. The term specifically may refer, without limitation, to a partially hydrolyzed polymer made from a polymer made from N-vinylamide monomers, in particular N-vinyl formamide monomers, or N-vinylamide monomers comprising a C1-C4 alkyl residue, such as , N-vinlyacetamid monomers, N-viny Ipropy lamide monomers, or N-vinylbutylamide monomers. The polymer is a partially hydrolyzed poly(N-vinylamide). Hence, it typically further comprises monomer units of vinyl-amine beneath monomer units of N-vinylamide, e.g. as the ones stated above. These vinylamine monomer units are present in the partially hydrolyzed N-vinylamide polymer in at least 10 mol-% based on the total amount of monomer units. Hence, the "partially hydrolyzed poly (N-vinylamide)” in line with the invention may be described as a copolymer of vinylamine monomer units and monomer units of a N-vinylformamide or a N-vinylamide with R2 = Ci to C4 alkyl, typically as a random copolymer. Typically, the nitrogen of the amide group may carry a hydrogen, a methyl or ethyl group, in particular a hydrogen.
[0068] The term "partially hydrolyzed poly (N-vinylamide)” as used herein more specifically may refer to a poly (N-viny la-mi de) comprising monomer units of a vinylamide and vinylamine; more specifically monomer units of vinylformamide and vinylamine. The term "partially hydrolyzed poly (N-vinylamide)” may typically encompass salts thereof, in particular pharmaceutically acceptable salts. Such a salt may be formed from the partially hydrolyzed poly (N-vinylamide) with an inorganic or an organic acid, or mixtures thereof. A salt of a partially hydrolyzed poly (N-vinylamide) may typically be formed with an inorganic acid like a hydrogen halogenide, e.g. hydrogen chloride or hydrogen bromide, or with sulfuric acid, or with an organic acid, like formic acid or acetic acid. Such salts may comprise also co-salts built from the base used for the hydrolysis of the poly (N-vinylamide) and the organic or inorganic acid, like sodium chloride, as well as respective salts of R2COO’, like sodium formiate. A preferred partially hydrolyzed poly (N-vinylamide) in line with the invention is a partially hydrolyzed poly (N-vinyl formamide) or a salt thereof, like a hydrochloride thereof.
[0069] Partially hydrolyzed poly (N-vinylamides) as well as polyvinylamine (PVAm) may be synthesized by polymerizing the amide monomer, e.g. N-vinylformamide (NVF), and hydrolyzing the resulting polymer, as the monomer, vinylamine, does not ordinarily exist in a free state. This process is well known in the art, see e.g., Kroner, M., et al., J. Prakt. Chem 2000, 342 (2), 115 and US Patent Re. 30,362. The degree of hydrolysis can be adjusted by stoichiometrically adjusting the amount of acid or base respectively used for hydrolysis.
[0070] In line with the invention, the partially hydrolyzed poly (N-vinylamide) may be a compound according to formula I or a salt thereof:
[0071]
[0072] NR^
[0073] formula I
[0074] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5, and wherein R1 = H or CO-R2 with R2 = H or C1-C4 alkyl. Further in formula I, in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl. Preferably, n is an integer between 350 to 40 000; more preferably, n is an integer between 1000 and 20000, even more preferably n is an integer between 1000 and 9000, still even more preferably n is an integer between 3000 and 9000. Still more preferably, the sum of all R1 must be 100 %.
[0075] The R1 is typically selected from any of CO-H, CO-CH3, and CO-C2H5.; more typically R1 is CO-H. Rxis typically H. In particular the R1 is CO-H and Rxis H. More typically, the partially hydrolyzed poly (N-vinylamide) may be regarded as a random copolymer.
[0076] In formula I, the terminal moieties of the polymer chain of the partially hydrolyzed poly (N-vinylamide) result from initiation and termination reactions which are known to a person skilled in the art.
[0077] Still more typically, the partially hydrolyzed poly (N-vinylamide), or salt thereof, comprises at most 90 mol-% of monomer units according to formula II:
[0078]
[0079] formula II
[0080] and at least 10 mol-% of monomer units according to formula III:
[0081]
[0082] formula IIIwherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5., more preferably R2 = H; and wherein Rx= H, CH3, or C2H5; preferably Rx= H.
[0083] The partially hydrolyzed poly (N-vinylamide) may comprise 90 to 4 mol-% of monomer units according to formula II and 10 to 96 mol-% of monomer units according to formula III, preferably 90 to 5 mol-% of monomer units according to formula II and 10 to 95 mol-% of monomer units according to formula III, more preferably 80 to 4 mol-% of monomer units according to formula II and 20 to 96 mol-% of monomer units according to formula III; even more preferably the poly (N-vinylamide) comprises 80 to 20 mol-% of monomer units according to formula II and 20 to 80 mol-% of monomer units according to formula III, still more preferably, 75 to 25 mol-% of monomer units according to formula II and 25 to 75 mol-% of monomer units according to formula III, still more preferably, 70 to 30 mol-% of monomer units according to formula II and 30 to 70 mol-% of monomer units according to formula III, even more preferably 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III. It is to be understood that, specifically, the sum of mol-% of monomer units of the partially hydrolyzed poly (N-vinylamide) equals 100 mol-%. More specifically, the sum of R1 equals 100 %.
[0084] Typically, the partially hydrolyzed poly (N-vinylamide) exhibits a degree of hydrolysis of at least 20 mol-%, preferably of at least 25 mol-%, more preferably of at least 30 mol-%. The mol-% of the partially hydrolyzed poly (N-vinylamide) can be determined as known in the art, for example by ion charge density measurements using polyelectrolyte titration, by determination of the amount of acid obtained due to the hydrolysis such as formic acid, by enzymatic determination based tools; by near infrared spectroscopy, or by NMR spectroscopy. Preferably, by polyelectrolyte titration or enzymatic determination of formic acid; suitable enzymatic test kits are commercially available; for example by Enzytec.
[0085] The partially hydrolyzed poly (N-vinylamide) may have a K-value between 10 and 250, preferably between 15 and 200, more preferably a K-value between 40 and 130, even more preferably a K-value between 45 and 95, still more preferable a K-value between 60 and 95. The K-value can be determined as known in the art using a capillary viscometer, typically in line with the international standard, DIN EN ISO 1628-1.
[0086] For the determination of the K-value, a 5 wt.% aqueous polymer solution may typically be prepared if the expected K-value is below 20, a 2 wt.% solution if the expected value is between 20 and 30, a 1 wt.% solution if the expected K-value is between 30 and 70, a 0.5 wt.% solution if the expected K-value is between 20-120, and a 0.1 wt.% solution if a K-value above 120 is expected. The solution may be placed in an Ubbelohde capillary viscometer (type 501 / 10 / 1) according to the manufacturer's instructions. The viscometer may be thermostated at 25.0 °C for at least 30 minutes. Subsequently, the flow time of the polymer solution tpoiybetween the calibrated marks may be automatically measured several times with an optical detector, and the arithmetic mean may be determined. To obtain the relative viscosity, it is typically necessary to determine the flow time of water tn2o before each measurement series. The relative viscosity is typically calculated according to the following equation (1).
[0087]
[0088] The K-value may be calculated from the relative viscosity rel using equation 2:
[0089] K_va|ue=^300 • c • logn rel + (C + 1 ,5 • c • lognrei)2+ 1 ,5 • c • lognrel- c
[0090]
[0091] 0,15 • c + 0,003 • c2
[0092] where:
[0093] 100-mPol
[0094] c = - — - = concentration in [%] (3),
[0095]
[0096] with mpoiy = mass (polymer) in [g], V = volume in [mL]
[0097] Still further, in line with present invention the cell culture may be treated in step a) with a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinyla-mide) according to formula IV or a salt thereof:
[0098]
[0099] NRv
[0100] xRd
[0101] 1formula IV,
[0102] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label.
[0103] Typically, the sum of R1 = H, COR2 and R3 is 100%. More typically, the mol-% of the monomer units with R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.00005 to 5.0, especially in the range of 0.0001 to 3.0, in particular in the range of 0.0005 to 2.0 mol-%.
[0104] Still more typically, the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are mixed in a weight ratio of 1 :99 to 99: 1 ; wherein the mol-% of the monomer units with R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.00005 to 5.0, especially in the range of 0.0001 to 3.0, in particular in the range of 0.0005 to 2.0 mol-%.
[0105] Still more typically, the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are mixed in a mixing weight ratio of 1:99 to 1:2, wherein the mol %of the monomer units with Ri = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.00005 to 0.5, or preferably in a mixing weight ratio of 99:1 to 2:1, wherein the mol % of the monomer units with R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.0001 to 5.0; even more preferably in the range of 0.0005 to 1.0 mol-%.
[0106] Even still more typically, the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are mixed in a weight ratio of 99:1 to 1:1 and the mol % of the monomer units R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.0005 to 5.0, especially in the range of 0.001 to 3.0, in particular in the range of 0.002 to 1.0 mol-%.
[0107] Even still more typically, the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are mixed in a weight ratio of 99:1 to 90:10 and the mol % of the monomer units R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.00005 to 0.5, especially in the range of 0.0001 to 0.3, in particular in the range of 0.0005 to 0.2 mol-%.
[0108] Particularly, a mixture refers to a homogenous distribution of the two or more compounds in liquid or solid form, more particularly in liquid form such as in aqueous solution.
[0109] In line with the present invention, the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV, that may be used in the respective mixture, preferably differ only in the label being present in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV; more preferably the degree of hydrolysis of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV may differ in a range of at most + / - 10 %, preferably at most + / - 5, even more preferably at most + / - 2 %, in particular at most + / - 1%, more particularly at most + / - 0.5 %. More preferably, the degree of hydrolysis of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is identical.
[0110] Still further, in line with present invention the cell culture may be treated in step a) with a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof:
[0111]
[0112] formula V,wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label. Typically, the sum of R1 = H, COR2 and R3 is 100%.
[0113] More typically, the mol % of the monomer units with R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinyl-amide) according to formula V is in the range of 0.00001 to 1.0, especially in the range of 0.0001 to 0.5, more especially in the range of 0.001 to 0.5 mol-%.
[0114] The term a "label” as used herein may refer, without limitation, to a compound adapted for making the presence of a molecule, in particular a partially hydrolyzed poly (N-vinylamide), comprising said label detectable. Typically, the label has a detectable property, typically an electrochemical, optical or / and enzymatic property. In particular, the label according to the present invention has an optically detectable property, more particularly the label is a fluorescent label also referred to as fluorescent marker. As will be understood, the parameter determined to detect said detectable property will also be referred to as "signal" or "detectable signal", in particular "fluorescent signal”. For the avoidance of doubt, it is noted that a signal may also be detected to be zero or below a detection limit.
[0115] Labels that may be used for this purpose are fluorescence markers capable of binding to, or binding to, the aminogroup of the polymer, e.g. the partially hydrolyzed poly (N-vinylamide). Typically, a fluorescent marker comprises at least one fluorophore comprising at least one functional group. More typically, the respective fluorophores comprise at least one amine-reactive functional group allowing the coupling with the amino group of the polymer, e.g. of the partially hydrolyzed poly (N-vinylamide). Suitable examples for "functional groups” include isothiocyanate groups (ITC), carboxylic acids (COOH) and reactive derivatives thereof, succinimidylesters (SE, NHS), sulfosuccin-imidylesters (SSE, NHS), tetrafluorophenylesters (TFPE), Sulfodichlorophenolesters (SDPE), azide groups, aldehyde groups. Still more typically, said functional group provides a permanent bond, in particular a covalent bond, between the fluorophore and the polymer according to the invention, e.g. the partially hydrolyzed poly (N-vinylamide).
[0116] Suitable examples for the fluorophores include carbocyanines, benzopyrylium type fluorophores, rhodamine and derivatives, fluorescein and derivatives, difluoroboron complexes, in particular Methoxycoumarin; Dansyl; Pyrene; Alexa Fluor® 350; Marina Blue® dye, Dapoxyl® dye; Dialkylaminocoumarin; Hydroxycoumarin; Cascade Blue® dye; Pacific Orange® dye; Alexa Fluor® 405; Cascade Yellow® dye; Pacific blue® dye; PyMPO, Alexa Fluor® 430; Fluorescein; Alexa Fluor® 488; Oregon Green® 488; Bod ipy® 493 / 503; Rhodamine Green dye; BODIPY® FL; 2',7'-Dichlorofluoroscein; Oregon Green® 514; Alexa Fluor® 514; 4',5'-Dichloro-2',7'-dimethoxyfluorescein; Eosin; Rhodamine 6G; Alexa Fluor®532; Bodipy®558 / 568; Bodipy®564 / 570; Lissamine rhodamine; Rhodamine Red dye; Bodipy®576 / 589; Alexa Fluor®568; X-rhodamine; Bod ipy®581 / 591; Bodipy® TR; Alexa Fluor® 594; Texas Red® dye; Naphthofluorescein; Alexa fluor® 610-X; Bodipy® 630 / 650; Malachite green; Alexa Fluor® 633; AlexaFluor® 635; Bod ipy® 650 / 665; Alexa Fluor® 647; Alexa Fluor® 660; Alexa Fluor® 680 A; Alexa Fluor® 700; Alexa Fluor® 750; Alexa Fluor® 790.
[0117] More particularly, examples for the fluorophores include Methoxycoumarin M1420MP, M1410; Dansyl D6104, D21; Pyrene P130, P6114, P24; Alexa Fluor® 350 A10168; AMCA A6118; Marina Blue® dye M10165, Dapoxyl® dye D10161, D10160; Dialkylaminocoumarin D126, D1421, D374, D1412; Bimane B30250; Hydroxycoumarin H185, H1428, H1193; Cascade Blue® dye C2284; Pacific Orange® dye P30253; Alexa Fluor® 405 A30000, A30100; Cascade Yellow® dye C10164; Pacific blue® dye P10163; PyMPO S6110, Alexa Fluor® 430 A10169; NBD S1 167, F486; Fluorescein C1359, C1360, C1904, C2210, C6164, C1311, F6106, F2181, F6129, F6130, C20050, D16, F143, F1906, F1907; Alexa Fluor® 488 A20000, A201000, A30005, A 30052; Oregon Green® 48806146, 06147, 06149, 06080; Bod ipy® 493 / 503 D2191; Rhodamine Green dye R 6107, R6113; BODIPY® FL D2183, D3834, D2184, D6140, D6102, D6184, B10006; 2',7'-Dichlorofluoroscein C368; Oregon Green® 51406138, 06139; Alexa Fluor® 514 A30002; 4',5'-Dichloro-2’,7'-dimethoxyfluorescein C6171 MP; Eosin E18; Rhodamine 6G C6127, C6128, C6157; Alexa Fluor®532; Bodipy®558 / 568 D2219; Bodipy®564 / 570 D2222; Lissamine rhodamine B L20, L1908; Rhodamine Red dye R6160; Bodipy®576 / 589 D2225; Alexa Fluor®568 A20003, A20103; X-rhodamine C6124, C6156; C6125, C6126, C1309, X491; Bodipy®581 / 591 D2228; Bodipy® TR D6116; Alexa Fluor® 594 A20004, A20104; Texas Red® dye T6134, T20175, T353, T 1905; Naphthofluorescein C652, C653; Alexa fluor® 610-X A30050; Bodipy® 630 / 650 D 10000; Malachite green M689; Alexa Fluor® 633 A20005, A20105; Alexa Fluor® 635; Bodipy® 650 / 665 D 100001; Alexa Fluor® 647 A20006, A20106; Alexa Fluor® 660 A 20007, A20107; Alexa Fluor® 680 A 20008, A20108; Alexa Fluor® 700 A 20010, A20110; Alexa Fluor® 750 A 20011, A20111; and Alexa Fluor® 790 A 30051.
[0118] Preferred fluorophores are fluorescein and derivatives, and preferred functional groups are isothiocycanates; particularly preferred are fluorescein and derivatives thereof with isothiocyanates as functional group, even more preferred are Fluorescein F143, F1906, F1907.
[0119] Useful labels may moreover be non-fluorescent dyes with a strong absorption in the visible range for FRET (fluorescence resonance energy transfer), e.g. QSY® 35 Q20133; QSY®7 Q10193; QSY®9 Q20131; QSY® 21 Q20132; or may be fluorinated compounds for detection via19F-NMR spectroscopy.
[0120] The term "labeled partially hydrolyzed poly (N-vinylamide)” as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art and is not to be limited to a special or customized meaning. The term specifically may refer, without limitation, to a labeled partially hydrolyzed polymer made from a polymer made from N-vinylamide monomers, in particular N-vinyl formamide monomers, or N-vinylamide monomers comprising a C1-C4 alkyl residue, such as, N-vinlyacetamid monomers, N-vinylpropylamide monomers, or N-vinyl-butylamide monomers, which is labeled. The polymer is a labeled partially hydrolyzed poly(N-vinylamide). Hence, it typically further comprises monomer units of vinylamine beneath monomer units of N-vinylamide, e.g. as the onesstated above, and monomer units of labeled vinylamine. These vinylamine monomer units are present in the labeled partially hydrolyzed N-vinylamide polymer in at least 10 mol-% based on the total amount of monomer units, and these labeled vinylamine monomer units are present in the labeled partially hydrolyzed N-vinylamide polymer of formula IV in at least 0.00005 mol-% based on the total amount of monomer units, or a present in the partially labeled hydrolyzed N-vinylamide polymer of formula V in at least 0.00001 mol-% based on the total amount of monomer units Hence, the "partially labeled hydrolyzed poly (N-vinylamide)” in line with the invention may be described as a copolymer of vinylamine monomer units and monomer units of a N-vinylformamide or a N-vinylamide with R2 = Ci to C4 alkyl, and monomer units of a labeled N-vinylamine, typically as a random copolymer. Typically, the nitrogen of the amide group may carry a hydrogen, a methyl or ethyl group, in particular a hydrogen, and the nitrogen of the labeled vinylamine monomer units may carry in addition to the label a hydrogen, a methyl or an ethyl group, in particular a hydrogen.
[0121] The term "labeled partially hydrolyzed poly (N-vinylamide)” as used herein more specifically may refer to a poly (N-vinylamide) comprising monomer units of a vinylamide, vinylamine and labeled vinylamine; more specifically monomer units of vinylformamide, vinylamine and labeled vinylamine, preferably fluorescently labeled vinylamine, particu-lary vinylamine substituted with CS-fluorescenyl, for example as R1 as depicted in formula IV or formula V. The term "labeled partially hydrolyzed poly (N-vinylamide)” may typically encompass salts thereof, in particular pharmaceutically acceptable salts. Such a salt may be formed from the labeled partially hydrolyzed poly (N-vinylamide) with an inorganic or an organic acid, or mixtures thereof. A salt of a labeled partially hydrolyzed poly (N-vinylamide) may typically be formed with an inorganic acid like a hydrogen halogenide, e.g. hydrogen chloride or hydrogen bromide, or with sulfuric acid, or with an organic acid, like formic acid or acetic acid. Such salts may comprise also co-salts built from the base used for the hydrolysis of the labeled poly (N-vinylamide) and the organic or inorganic acid, like sodium chloride, as well as respective salts of R2COO’, like sodium formiate. A preferred labeled partially hydrolyzed poly (N-vinylamide) in line with the invention is a labeled partially hydrolyzed poly (N-vinyl formamide) or a salt thereof, like a hydrochloride thereof, preferably a fluorescently labeled partially hydrolyzed poly (N-vinyl formamide) or a salt thereof, like a hydrochloride thereof, more preferably a partially hydrolyzed poly (N-vinyl formamide) labeled with fluorescein or a salt thereof, like a hydrochloride thereof.
[0122] In line with the invention, the labeled partially hydrolyzed poly (N-vinylamide) of formula IV may be a compound according to formula IV or a salt thereof:
[0123]
[0124] formula IV,
[0125] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5, and wherein R1 = H or CO-R2 with R2 = H or C1-C4 alkyl. Further in formula IV, in at least 10 mol-% of monomer units R1 = H, in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl, and in at least 0.00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label. Preferably, n is an integer between 350 to 40000; more preferably, n is an integer between 1000 and 20 000, even more preferably n is an integer between 1000 and 9000, still even more preferably n is an integer between 3000 and 9000. Still more preferably, the sum of all R1 must be 100%.
[0126] For the at most 90 mol-% of the monomer units, R1 is typically selected from any of CO-H, CO-CH3, and CO-C2H5.; more typically R1 is CO-H. Rxis typically H. In particular the R1 is CO-H and Rxis H; for the at least 0.00005 mol-% of the monomer units R1 = R3 = a label, R3 is typically a fluorescent label, more typically a fluorescein label. Rxis typically H. In particular, the R1 = R3 is a fluorescein label and Rxis H. More typically, the labeled partially hydrolyzed poly (N-vinylamide) may be regarded as a random copolymer.
[0127] In formula IV, the terminal moieties of the polymer chain of the labeled partially hydrolyzed poly (N-vinylamide) result from initiation and termination reactions which are known to a person skilled in the art.
[0128] Still more typically, the labeled partially hydrolyzed poly (N-vinylamide) of formula IV, or salt thereof, comprises at most 90 mol-% of monomer units according to formula II:
[0129]
[0130] R2
[0131] formula II
[0132] and at least 10 mol-% of monomer units according to formula III:
[0133]
[0134] NRXH
[0135] formula III
[0136] and at least 0.00005 mol % of monomer units according to formula VI:
[0137]
[0138] NRXR3
[0139] formula VI
[0140] wherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5., more preferably R2 = H; and wherein Rx= H, CH3, or C2H5; preferably Rx= H, and wherein Rs.= a label, preferably R3 = a fluorescent label, more preferably Rs= fluorescein label.
[0141] The labeled partially hydrolyzed poly (N-vinylamide) of formula IV may comprise 90 to 4 mol-% of monomer units according to formula II and 10 to 96 mol-% of monomer units according to formula III and 0.00005 to 5.0 mol-% of monomer units according to formula VI, preferably 90 to 5 mol-% of monomer units according to formula II and 10 to 95 mol-% of monomer units according to formula III and 0.00005 to 5.0 mol-% of monomer units according to formula VI, more preferably 80 to 4 mol-% of monomer units according to formula II and 20 to 96 mol-% of monomer units according to formula III and 0.0001 to 3.0 mol-% of monomer units according to formula VI; even more preferably the poly (N-vinylamide) comprises 80 to 20 mol-% of monomer units according to formula II and 20 to 80 mol-% of monomer units according to formula III and 0.0001 to 3.0 mol-% of monomer units according to formula VI, still more preferably, 75 to 25 mol-% of monomer units according to formula II and 25 to 75 mol-% of monomer units according to formula III and 0.00005 to 5.0 mol-% of monomer units according to formula VI, still more preferably, 70 to 30 mol-% of monomer units according to formula II and 30 to 70 mol-% of monomer units according to formula III and 0.00005 to 5.0 mol-% of monomer units according to formula VI, even more preferably 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0.00005 to 5.0 mol-% of monomer units according to formula VI, in particular 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0.0001 to 3.0 mol-% of monomer units according to formula VI, even more particular 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0.0005 to 2.0 mol-% of monomer units according to formula VI; especially 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0,001 to 1.0 mol-% of monomer units according to formula V. It is to be understood that, specifically, the sum of mol-% of monomer units of the labeled partially hydrolyzed poly (N-vinylamide) of formula IV equals 100 mol-%. More specifically, the sum of R1 equals 100 %.
[0142] Typically, the labeled partially hydrolyzed poly (N-vinylamide) of formula IV exhibits a degree of hydrolysis of at least 20 mol-%, preferably of at least 25 mol-%, more preferably of at least 30 mol-%. The mol-% of the labeled partially hydrolyzed poly (N-vinylamide) of formula IV can be determined as known in the art, for example by ion charge density measurements using polyelectrolyte titration, by determination of the amount of acid obtained due to the hydroly-sis such as formic acid, by enzymatic determination based tools; by near infrared spectroscopy, or by NMR spectroscopy. Preferably, by polyelectrolyte titration or enzymatic determination of formic acid; suitable enzymatic test kits are commercially available; for example by Enzytec.
[0143] The labeled partially hydrolyzed poly (N-vinylamide) of formula IV may have a K-value between 10 and 250, preferably between 15 and 200, more preferably a K-value between 40 and 130, even more preferably a K-value between 45 and 95, still more preferable a K-value between 60 and 95. The K-value can be determined as known in the art using a capillary viscometer, typically in line with the international standard, DIN EN ISO 1628-1.
[0144] The determination of the K-value is stated somewhere else in this application.
[0145] In line with the invention, the labeled partially hydrolyzed poly (N-vinylamide) of formula V may be a compound according to formula V or a salt thereof:
[0146]
[0147] formula V,
[0148] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5, and wherein R1 = H or CO-R2 with R2 = H or C1-C4 alkyl. Further in formula V, in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl and in at least 0.00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label. Preferably, n is an integer between 350 to 40000; more preferably, n is an integer between 1000 and 20 000, even more preferably n is an integer between 1000 and 9000, still even more preferably n is an integer between 3000 and 9000. Still more preferably, the sum of all R1 must be 100 %.
[0149] For the at most 90 mol% of the momomer units the R1 is typically selected from any of CO-H, CO-CH3, and CO-C2H5.; more typically R1 is CO-H. Rxis typically H. In particular the R1 is CO-H and Rxis H; for the at least 0.00001 mol % of the monomer units R1 = R3 = a label, R3 is typically a fluorescent label, more typically a fluorescein label. Rxis typically H. In particular the R1 = R3 is a fluorescein label and Rxis H. More typically, the labeled partially hydrolyzed poly (N-vinylamide) may be regarded as a random copolymer.
[0150] In formula V, the terminal moieties of the polymer chain of the labeled partially hydrolyzed poly (N-vinylamide) result from initiation and termination reactions which are known to a person skilled in the art.Still more typically, the labeled partially hydrolyzed poly (N-vinylamide) of formula V, or salt thereof, comprises at most 90 mol-% of monomer units according to formula II:
[0151]
[0152] R2
[0153] formula II
[0154] and at least 10 mol-% of monomer units according to formula III:
[0155]
[0156] NRXH
[0157] formula III
[0158] J
[0159] and at least 0.00001 mol % of monomer units according to formula VI:
[0160]
[0161] NRXR3
[0162] formula VI
[0163] wherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5., more preferably R2 = H; and wherein Rx= H, CH3, or C2H5; preferably Rx= H and wherein Rs.= a label, preferably R3 = a fluorescent label, more preferably Rs= fluorescein label.
[0164] The labeled partially hydrolyzed poly (N-vinylamide) of formula V may comprise 90 to 4 mol-% of monomer units according to formula II and 10 to 96 mol-% of monomer units according to formula III and 0.00001 to 1.0 mol-% of monomer units according to formula VI, preferably 90 to 5 mol-% of monomer units according to formula II and 10 to 95 mol-% of monomer units according to formula III and 0.00001 to 1,0 mol-% of monomer units according to formula VI, more preferably 80 to 4 mol-% of monomer units according to formula II and 20 to 96 mol-% of monomer units according to formula III and 0.00001 to 1.0 mol-% of monomer units according to formula VI; even more preferably the poly (N-vinylamide) comprises 80 to 20 mol-% of monomer units according to formula II and 20 to 80 mol-% of monomer units according to formula III and 0.00005 to 0.8 mol-% of monomer units according to formula VI, still more preferably, 75 to 25 mol-% of monomer units according to formula II and 25 to 75 mol-% of monomer units according to formula III and 0.00001 to 1.0 mol-% of monomer units according to formula VI, still more preferably, 70 to 30 mol-% of monomer units according to formula II and 30 to 70 mol-% of monomer units according to formula III and0.00001 to 1.0 mol-% of monomer units according to formula VI, even more preferably 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0.00001 to 1.0 mol-% of monomer units according to formula VI, in particular 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0.00001 to 1.0 mol-% of monomer units according to formula VI, even more particular 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0.00005 to 0.8 mol-% of monomer units according to formula VI, even more particular 60 to 40 mol-% of monomer units according to formula II and 40 to 60 mol-% of monomer units according to formula III and 0.0001 to 0.5 mol-% of monomer units according to formula VI. It is to be understood that, specifically, the sum of mol-% of monomer units of the partially hydrolyzed poly (N-vinylamide) equals 100 mol-%. More specifically, the sum of Ri equals 100 mol-%.
[0165] Typically, the labeled partially hydrolyzed poly (N-vinylamide) of formula V exhibits a degree of hydrolysis of at least 20 mol-%, preferably of at least 25 mol-%, more preferably of at least 30 mol-%. The mol-% of the labeled partially hydrolyzed poly (N-vinylamide) of formula V can be determined as known in the art, for example by ion charge density measurements using polyelectrolyte titration, by determination of the amount of acid obtained due to the hydrolysis such as formic acid, by enzymatic determination based tools; by near infrared spectroscopy, or by NMR spectroscopy. Preferably, by polyelectrolyte titration or enzymatic determination of formic acid; suitable enzymatic test kits are commercially available; for example by Enzytec.
[0166] The labeled partially hydrolyzed poly (N-vinylamide) of formula V may have a K-value between 10 and 250, preferably between 15 and 200, more preferably a K-value between 40 and 130, even more preferably a K-value between 45 and 95, still more preferable a K-value between 60 and 95. The K-value can be determined as known in the art using a capillary viscometer, typically in line with the international standard, DIN EN ISO 1628-1.
[0167] The determination of the K-value is stated somewhere else in this application.
[0168] The labeled partially hydrolyzed poly (N-vinylamides) according to formula IV or V can be synthesized using methods known in the art, in particular in a method as follows in case the respective fluorophores comprise an isothiocyanate group as "functional group”:
[0169] General procedure 1 :
[0170] The respective partially hydrolyzed poly(N-vinylamide) of formula I is typically diluted with water until the solution reaches a viscosity appropriate for easy stirring and effective mixing. An appropriate solution of the desired fluoro-phore comprising an isothiocyanate group in acetone, dimethylsulfoxide or dimethylformamide may be added at room temperature while stirring. Typically, the stirring may be continued for up to 8h. Dialysis in deionized water with an appropriate molecular weight cut-off (e.g. of 3.5 kDa, 10 kDa) may be done until no fluorescence in the permeate is detected after filtration through a 0.45pm syringe.General procedure 2:
[0171] The respective partially hydrolyzed poly(N-vinylamide) of formula I may if needed be diluted with water until the solution reaches a viscosity appropriate for easy stirring and effective mixing. After adjusting to a pH of 11, typically, by adding a 10% sodium hydroxide solution, an appropriate amount of fluorescein-5-isothiocyanat (FITC) may be added in dimethylsulfoxide at ambient temperature. After further stirring the pH may be adjusted to 8 by addition of 30% hydrochloric acid solution. The mixture obtained thereby may be used without further purification.
[0172] The step "treating a cell culture with a partially hydrolyzed poly (N-vinylamide)” refers to adding to the cell culture said partially hydrolyzed poly (N-vinylamide), typically in a sufficient amount and more typically mixing the partially hydrolyzed poly (N-vinylamide) with the cell culture. The partially hydrolyzed poly (N-vinylamide) is more typically added in form of an aqueous solution. In line with the invention, the step "treating a cell culture with a mixture of a partially hydrolyzed poly (N-vinylamide) and a labeled partially hydrolyzed poly (N-vinylamide)” refers to adding to the cell culture said mixture of the partially hydrolyzed poly (N-vinylamide) and the labeled partially hydrolyzed poly (N-vinyla-mide), typically in a sufficient amount and more typically mixing the partially hydrolyzed poly (N-vinylamide) and the labeled partially hydrolyzed poly (N-vinylamide) with the cell culture. The partially hydrolyzed poly (N-vinylamide) and the labeled partially hydrolyzed poly (N-vinylamide) are more typically added separately or together in form of aqueous solution(s). And in line with the invention the step "treating a cell culture with a labelled partially hydrolyzed poly (N-vinylamide)” refers to adding to the cell culture said labeled partially hydrolyzed poly (N-vinylamide), typically in a sufficient amount and more typically mixing the labeled partially hydrolyzed poly (N-vinylamide) with the cell culture. The labeled partially hydrolyzed poly (N-vinylamide) is more typically added in form of an aqueous solution
[0173] Adding a sufficient amount of said partially hydrolyzed poly (N-vinylamide) or said labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof, may in in particular refer to adding at least 50 ppm of the partially hydrolyzed poly (N-vinylamide) into the cell culture or said labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof, respectively i.e. into the fermentation medium comprising the cells. Hence, typically, the amount in ppm refers to weight of the dry matter of the partially hydrolyzed poly (N-vinylamide) or said labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof in relation to the total volume of the cell culture plus the volume of the added polymer solution; more typically, the amount in ppm refers to weight of the dry matter of the partially hydrolyzed poly (N-vinylamide) or said labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof calculated on the pure polymer; excluding salt content if any in relation to the total volume of the cell culture plus the volume of the added polymer solution. More particularly, at least 100 ppm, more particularly at least 300 ppm, even more particularly at least 500 ppm of said partially hydrolyzed poly (N-vinyl amide) or said labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof, respectively may be added to the cell culture. Further, at most 5000 ppm or at most 3000 ppm of said partially hydrolyzed poly (N-vinylamide) or said labeled partially hydrolyzed poly (N-vinylamide) or a mixturethereof, respectively may typically be added to the cell culture. Preferably, the partially hydrolyzed poly (N-vinyla-mide) or said labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof is added in a range of 300 ppm to 2000 ppm, more preferably in a range of 500 ppm to 1500 ppm.
[0174] The mixing may be achieved by any means and methods as known in the art for example by agitating, by stirring or by shaking the cell culture to achieve a homogenous mixture or suspension. The mixing typically is performed for a time sufficient to achieve a homogenous mixture or suspension. Said time may be in the range of 1 min to 2 hours.
[0175] Moreover, the treating step may comprise an incubation step, wherein the mixture or suspension is maintained with mixing and / or without mixing. Said incubation may last for 1 min up to 2 hours. Preferably, the incubation step comprises mixing the mixture or suspension further. Following the further mixing, the mixture may be maintained without mixing.
[0176] Typically, the step of treating, in particular the incubation step, allows flocculation to occur. The term ..flocculation" commonly refers to a process in which finely dispersed matter in aqueous systems is converted into larger structures, so called flocs. These flocs typically settle easily on the influence of hydrophilic high molecular weight polymers, so called flocculants or flocculating agents. In line with the invention flocculation in particular refers to a process, in which fragments of host cells and other finely dispersed matter such as host cell DNA and / or host cell proteins in a fermentation medium are converted into larger structures, so called flocs, that settle easily on the influence of the partially hydrolyzed poly (N-vinylamide) or the labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof. More particularly, flocculation occurs during the step of treating the cell culture with a partially hydrolyzed poly (N-vinylamide) or said labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof. Typically, said flocs may be removed by a solid-liquid separation step as described elsewhere herein. Still more typically, flocculation occurs without requiring any stimulus. This specifically means that no change in pH, temperature, conductivity, salt or ion concentration and / or no additional reagent, such as a complexing agent, is required for allowing flocculation to occur. In particular, the partially hydrolyzed poly (N-vinylamide) or the labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof according to the present invention do not constitute stimulus responsive polymers.
[0177] A suitable flocculant in line with the present invention is the herein described partially hydrolyzed poly (N-vinylamide) or the herein described labeled partially hydrolyzed poly (N-vinylamide) or the herein described mixture thereof. Typically, the partially hydrolyzed poly (N-vinylamide) or labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof is added as an aqueous solution, as a solid material, more typically as a powder or granulate; preferably as an aqueous solution. Typically, the partially hydrolyzed poly (N-vinylamide) or the labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof may first be suspended or dissolved in an aqueous solvent and then be added in form of a liquid, i.e. as an aqueous solution to the cell culture.The method according to the invention may further comprise adjusting or maintaining the pH to / at a value between pH 5.0 to 7.5 , in particular to / at a value between pH 5.0 and 7.0, preferably to / at a value between pH 5.5 and 6.5, more preferably to / at a value between pH 5.8 and 6.2; even more preferably to / at a value between pH 5.9 and 6.1; still more preferably to / at a value of pH 6. Typically the method according to the invention may further comprise adjusting or maintaining the pH to / at a value between pH 5.0 and 7.0, preferably to / at a value between pH 5.5 and 6.5. The pH may preferably be adjusted prior to or simultaneous with the treating in step a).
[0178] Separating the cell culture into a precipitate and a supernatant / liquid fraction
[0179] Further, the method according to the invention comprises a step b) of separating the cell culture into a precipitate and a supernatant / liquid fraction. As described elsewhere herein, the cell culture comprises cells secreting the antibody or fragment thereof into the cultivation medium. Hence, separating the cell culture into a precipitate / solid fraction and a supernatant / liquid fraction, typically results in the separation of the liquid fraction comprising the antibody or fragment thereof from the biomass, such as the cells, debris of cells. More typically, the flocculants, in particular, the partially hydrolyzed poly (N-vinylamide) according to formula I as described elsewhere herein or the mixture of the partially hydrolyzed poly (N-vinylamide) of formula I and the labeled partially hydrolyzed poly (N-vinylamide) of formula IV, or the labeled partially hydrolyzed poly (N-vinylamide) of formula V, respectively, may be separated together with the biomass.
[0180] The term "solid fraction” relates to the solid matter obtained by using a solid / liquid separation process as described elsewhere herein. Typically, a solid fraction may be a precipitate, a sediment, a pellet, a filter cake, an adsorbate. It is to be noted that the term "precipitate” is understood to relate to the solid matter that is obtained by precipitation or centrifugation, typically in form of a deposit such as a deposit on the bottom of a vessel. The term "liquid fraction” relates to the liquid matter obtained by using a solid / liquid separation process as described elsewhere herein. Typically, a liquid fraction may be a supernatant, a flow-through, a filtrate. A "supernatant” typically refers to the liquid fraction obtained by precipitation or centrifugation.
[0181] Without wishing to be bound by theory, the present inventors believe that the treatment with the partially hydrolyzed poly (N-vinylamide), the labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof allows for an efficient removal of host cell DNA and host cell proteins, particularly and surprisingly high risk host cell proteins may efficiently be removed. Said removal may be achieved by separating the cell culture into a precipitate and a supernatant / liquid fraction after treating the cell culture with the partially hydrolyzed poly (N-vinylamide), the labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof, respectively, as described herein. Typically, the antibody or fragment thereof is in the supernatant, i.e. the liquid fraction; while more typically host cell, host cell DNA and host cell proteins are separated as a precipitate or solid fraction.The separation may comprise a solid-liquid separation step selected from filtration, centrifugation, sedimentation, decantation; preferably filtration, more preferably in depth filtration.
[0182] In particular, said solid / liquid separation techniques result in at least a fraction comprising the liquid part of the cell culture including the fermentation medium and compounds solubilized in the fermentation medium including the antibody or fragment thereof, typically referred to as "liquid fraction” or "supernatant”, and at least a "solid fraction” or "precipitate" comprising the solid parts present in the cell culture including the biomass, such as the cells, debris of cells. Preferably, the liquid fraction of the fermentation medium comprises the antibody or fragment thereof.
[0183] The method may further comprise a step of obtaining the antibody or fragment thereof. The phrase "obtaining the antibody or fragment thereof” as used herein typically refers to obtaining the antibody or fragment thereof from the cell culture by appropriate purification techniques including techniques known in the art and including those solid / liquid separation techniques described elsewhere herein. More preferably, the step of obtaining the antibody or fragment thereof may involve further purification steps. Typically, the liquid fraction or supernatant comprising the antibody may be subjected to one or more of the following further purification steps: chromatography such as anion-exchange chromatography, cation-exchange chromatography, hydrophobic-interaction chromatography, affinity chromatography; filtration such as micro-filtration, ultrafiltration; crystallization, precipitation for example by using ammonium sulfate and extraction for example by using multiphase systems. These purification steps are known in the art.
[0184] The present invention further contemplates an antibody or fragment thereof obtained by or obtainable by the method according to the invention.
[0185] Said antibody or fragment thereof is advantageous as it comprises low levels of host cell proteins, in particular low levels of high risk host cell proteins.
[0186] "High risk host cell proteins” are commonly regarded as proteins that may co-purify with biopharmaceutical products and are considered high-risk since they include proteins that are immunogenic, biologically active, or enzymatically active with the potential to degrade either product molecules or excipients used in a formulation of said products (Jones et al. 2001 Biotechnol Bioeng. 2021;118:2870-2885). "High risk host cell proteins” include for example 78 kDA glucose regulated protein (GRP78, BiP), Protein S100-A6 (S100A6), Clusterin (Clu), Cathepsin B (CatB), pro-collagen-lysine 2-oxoglutarate 5-dioxygenase 1 (PLOD1), Phospholipase B-like 2 (PLBL2), Serine protease (HTRA1), Cathepsin L (CatL), Cathepsin Z (CatZ), Lipoprotein lipase (LPL), C-C motif chemokine (CCL), Monocyte chemoattractant protein-1 (MCP-1). High risk host cell proteins may be categorized according to their effect on the product molecule or on the patient. Some important high risk host cell proteins and their potential negative impacts are exemplified in Table 1.
[0187] Table 1: Examples of high risk host cell proteins and their impactIdentified HCP Impact Type of Impact
[0188] 78 kDa glucose regulated protein(GRP78, BiP) drug quality aggregation of drugs Protein S100-A6 (S10A6) immunogenicity immunogenic response Clusterin (CLU) immunogenicity immunogenic response Cathepsin B (CatB) drug quality fragmentation of drugs Procollagen-lysine 2-oxoglutarate 5-deoxygenase_1
[0189] (PLOD1) immunogenicity immunogenic response Carboxypeptidase D (Cpd) drug quality modification of drug Phospholipase B-like 2 (PLBL2) immunogenicity immunogenic response Serine protease (HTRA1) drug quality modification of drug Cathepsin L (CatL) drug quality fragmentation of drugs Lysosomal Acid Lipase (LAL) formulation degradation of polysorbates Cathepsin Z (CatZ) drug quality fragmentation of drugs Matrix metalloproteinase-19 (MMP-19) drug quality degradation of product Lipoprotein Lipase (LPL) formulation degradation of polysorbates C-C motif chemokine; Monocyte Chemoattractant Protein-1 biological function
[0190] (MCP-1) in human cytokine release Transforming Growth Factor-b1 (TGF-b1) biological function cytokine release
[0191]
[0192] in human
[0193] Moreover, the present invention relates to a composition comprising said antibody or said fragment obtained by or obtainable by the method according to the invention. Preferably, the composition consists of the supernatant obtained by the method according to the invention, more preferably the composition is an aqueous composition. The composition may be a semi-purified composition. It may typically be regarded as semi-purified as it comprises residual host cell DNA and / or host cell proteins.
[0194] The composition may comprise at most 5%, preferably at most 2 % of residual DNA and / or low levels of one or more of the following host cell proteins (HCPs): 78 kDA glucose regulated protein (GRP78, BiP), Clusterin, Cathepsin B, procollagen-lysin2-oxoglutarate 5-deoxygenaose 1 (PLOD1).
[0195] The % of residual DNA in the preparation may be determined by a standard DNA quantification assay involving DNA staining by fluorescence dyes like ethidium bromide, 4',6-diamidino-2-phenylidole (DAPI), SYBR Green (SG) or PicoGreen. These assays are known in the art. The % residual DNA may be determined by determining the amount of DNA to a reference. A suitable reference may be an untreated sample of the cell culture; such as a sample that is not treated with the partially hydrolyzed poly (N-vinylamide), the labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof; but typically is processed according to the method of purification except that the step a) lacks the partially hydrolyzed poly (N-vinylamide), the labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof, respectively.Typically, low levels of host cell proteins refer to reduced levels of said host cell proteins in comparison to a reference, in particular in comparison to a sample not subjected to treatment with partially hydrolyzed poly (N-vinylamide), labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof, respectively. "Reduced level of host cell protein” refers to a reduction of at least 10 %, preferably to at least 20 %, more preferably to at least 30 % reduction in the host cell protein content as determined by enzyme linked immunosorbent assay (ELISA) in comparison to an untreated sample. Typically, a 10 % to 40 % of reduction of host cell protein content can be seen in comparison to an untreated sample. Advantageously, this level of reduction appears to be higher than what can be achieved when treating the cell culture with pDADMAC.
[0196] Further, the present invention relates to a use of a partially hydrolyzed poly (N-vinylamide), a labeled partially hydrolyzed poly (N-vinylamide) or a mixture thereof as defined elsewhere herein in more detail for antibody purification. Said purification may be a purification method according to the present invention.
[0197] Moreover, the invention relates to a composition comprising a partially hydrolyzed poly (N-vinylamide) according to formula I or salt thereof, a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or salt thereof, or a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or salt thereof as defined elsewhere herein, cell culture cells and a shear protectant. Further, the invention encompasses a kit of parts comprising (I) a partially hydrolyzed poly (N-vinylamide) according to formula I or salt thereof, or a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or salt thereof, or a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or salt thereof as defined elsewhere herein as a first constituent and (II) a shear protectant as a second constituent. Preferably the first and the second constituent are packaged in separate containers. More preferably the kit of parts is used for purifying an antibody or fragment thereof from an antibody secreting cell culture; even more preferably is used in the method for purifying an antibody or fragment thereof from an antibody secreting cell culture as defined elsewhere herein.
[0198] Moreover, the invention relates to a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or salt thereof as defined elsewhere herein.
[0199] Further the invention relates to a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or salt thereof as defined elsewhere herein.
[0200] Also, the invention further relates to a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or salt thereof as defined elsewhere herein.The explanations and interpretations of the terms made above apply mutatis mutandis to the embodiments described herein below.
[0201] Summarizing and without excluding further possible embodiments, the following embodiments may be envisaged. Therein, the respective optional features may be realized in an isolated fashion as well as in any arbitrary feasible combination, as the skilled person will realize. The scope of the invention is not restricted by the preferred embodiments.
[0202] The following embodiments are preferred embodiments of the method of the invention:
[0203] 1. A method for purifying an antibody or fragment thereof from an antibody secreting cell culture, comprising at least the following steps:
[0204] a) treating the cell culture with
[0205] (I) a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof
[0206]
[0207] NRXR1
[0208] formula I
[0209] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl;
[0210] (II) a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof:
[0211]
[0212] NRXR1
[0213] formula IV,
[0214] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; or
[0215] (ill) a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof:
[0216]
[0217] NRXR1
[0218] formula V,
[0219] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label;
[0220] and
[0221] b) separating the cell culture into a precipitate / solid and a supernatant / liquid fraction.
[0222] 2. The method according to embodiment 1 , wherein step a) is described in subsection i) of step a) of embodiment 1.
[0223] 3. The method according to embodiment 1 , wherein step a) is described in subsection ii) of step a) of embodiment 1.
[0224] 4. The method according to embodiment 1, wherein step a) is described in subsection iii) of step a) of embodiment 1.
[0225] 5. The method according to embodiment 2 or 3, wherein the partially hydrolyzed poly (N-vinylamide) according to formula I, or salt thereof,
[0226] comprises at most 90 mol-% of monomer units according to formula II
[0227]
[0228] formula II , and
[0229] at least 10 mol-% of monomer units according to formula III:
[0230]
[0231] NRXH
[0232] formula III
[0233] wherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5; and wherein Rx= H, CH3, or C2H5; preferably Rx= H.
[0234] 6. The method according to embodiment 5, wherein in the partially hydrolyzed poly (N-vinylamide) according to formula I, or salt thereof, R2 = H or CH3 and Rx= H, preferably wherein R2 = H and Rx= H.
[0235] 7. The method according to embodiment 5 or 6, wherein the partially hydrolyzed poly (N-vinylamide) according to formula I comprises 80 to 4 mol-% of monomer units according to formula II and 20 to 96 mol-% of monomer units according to formula III; preferably wherein the partly hydrolyzed poly (N-vinylamide) according to formula I comprises 80 to 20 mol-% of monomer units according to formula II and 20 to 80 mol-% of monomer units according to formula III.
[0236] 8. The method according to any of the preceding embodiments, wherein the partially hydrolyzed poly (N-vinyla-mide) of formula I used in step a) I) or step a) II) exhibits a degree of hydrolysis of at least 20 mol-%, preferably of at least 25 mol-%, more preferably of at least 30 mol-%, in particular of 30 mol% to 60 mol%.
[0237] 9. The method according to any of the preceding embodiments, wherein the labeled partly hydrolyzed poly (N-vinylamide) according to formula IV used in step a)ii), or wherein the labeled partly hydrolyzed poly (N-vinylamide) according to formula V used in step a) ill) comprises 80 to 4 mol-% of monomer units according to formula II and 20 to 96 mol-% of monomer units according to formula III; preferably wherein the labeled partially hydrolyzed poly (N-vinyl-amide) comprises 80 to 20 mol-% of monomer units according to formula II and 20 to 80 mol-% of monomer units according to formula III.
[0238] 10. The method according to any of the preceding embodiments, wherein the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV used in step a) II) or wherein the labeled partly hydrolyzed poly (N-vinylamide) according to formula V used in step a) ill) exhibits a degree of hydrolysis of at least 20 mol-%, preferably of at least 25 mol-%, more preferably of at least 30 mol-%.
[0239] 11. The method according to any of the preceding embodiments, wherein for the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV the mol % of the monomer units R1 = R3 = a label is in the range of 0.00005 to 5.0, especially in the range of 0.0001 to 3.0, in particular in the range of 0.0005 to 2.0.12. The method according to any of the preceding embodiments, wherein in the mixture of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV used in step a) ii) the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are present in a wt% ratio of 99: 1 to 1 :99, preferably in a wt ratio of 99:1 to 1:1, more preferably in a wt ratio of 99:1 to 80:2, even more preferably in a wt ratio of 99:1 to 90:10.
[0240] 13. The method according to any of the preceding embodiments, wherein the partially hydrolyzed poly (N-vinyla-mide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are mixed in a ratio of 1 :99 to 99: 1 ; preferably in a mixing ratio of 1 :99 to 1 :2, wherein the mol % of the monomer units Ri = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.00005 to 0.5 , or preferably in a mixing ratio of 99:1 to 2:1, wherein the mol % of the monomer units R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.0001 to 5.0.
[0241] 14. The method according to any of the preceding embodiments, wherein the partially hydrolyzed poly (N-vinyla-mide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are mixed in a ratio of 99:1 to 1 :1, wherein the mol % of the monomer units R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0.0005 to 5.0, preferably in the range of 0.001 to 3.0, even more preferably in the range of 0.002 to 1.0.
[0242] 15. The method according to any of the preceding embodiments, wherein the partially hydrolyzed poly (N-vinyla-mide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are mixed in a ratio of 99:1 to 90:10 and the mol % of the monomer units R1 = R3 = a label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is in the range of 0,00005 to 0.5, especially in the range of 0.0001 to 0.3, in particular in the range of 0.0005 to 0,2.
[0243] 16. The method according to any of the preceding embodiments wherein in the mixture of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV used in step a) ii) the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV differ only in the label being present in the partially hydrolyzed poly (N-vinylamide) according to formula IV, preferably the degree of hydrolysis of partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV differ in a range of at most + / - 10 %, preferably at most + / - 5, even more preferably at most + / - 2 %, in particular at most + / - 1%, more particularly at most + / - 0.5 %.
[0244] 17. The method according to any of the preceding embodiments wherein in the mixture of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formulaIV used in step a) ii) the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV differ only in the label being present in the partially hydrolyzed poly (N-vinylamide) according to formula IV and the degree of hydrolysis of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is identical.
[0245] 18. The method according to any of the preceding embodiments wherein the mol % of the monomer units Ri = R3 = a label according to formula V is in the range of 0.00001 to 1.0, especially in the range of 0.0001 to 0.5.
[0246] 19. The method according to any of the preceding embodiments, wherein the label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is a fluorescent label.
[0247] 20. The method according to any of the preceding embodiments, wherein the label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV is a fluorescent label prepared with an isothiocyanate of fluorescein and derivatives thereof.
[0248] 21. The method according to any of the preceding embodiments, wherein the label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula V is a fluorescent label.
[0249] 22. The method according to any of the preceding embodiments, wherein the label in the labeled partially hydrolyzed poly (N-vinylamide) according to formula V is a fluorescent label prepared with an isothiocyanate of fluorescein and derivatives thereof.
[0250] 23. The method according to any of the preceding embodiments, wherein the sum of mol-% of monomer units of the partially hydrolyzed poly (N-vinylamide) according to formula I in the partially hydrolyzed poly (N-vinylamide) according to formula I equals 100 mol-%, preferably the sum of R1 equals 100 %., even more preferably the sum of R1 = H, COR2 equals to 100%.
[0251] 24. The method according to any of the preceding embodiments, wherein the sum of mol-% of monomer units of the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV in the partially hydrolyzed poly (N-vinyla-mide) according to formula IV equals 100 mol-%, preferably the sum of R1 equals 100 %., even more preferably the sum of R1 = H, COR2 and R3 equals to 100%.
[0252] 25. The method according to any of the preceding embodiments, wherein the sum of mol-% of monomer units of the labeled partially hydrolyzed poly (N-vinylamide) according to formula V in the partially hydrolyzed poly (N-vinyla-mide) according to formula V equals 100 mol-%, preferably the sum of R1 equals 100 %., even more preferably the sum of R1 = H, COR2 and R3 equals to 100%.26. The method according to any of the preceding embodiments, wherein the degree of hydrolysis is determined by ion charge density measurements using polyelectrolyte titration, determination of the amount of acid obtained due to the hydrolysis such as formic acid, enzymatic based tools; near infrared spectroscopy, or NMR spectroscopy.
[0253] 27. The method according to any of the preceding embodiments, wherein the partially hydrolyzed poly (N-vinyla-mide) has a K-value between 10 and 250, preferably between 15 and 200, more preferably between 45 and 95, in particular between 60 and 95.
[0254] 28. The method according to any of the preceding embodiments, wherein the antibody or fragment thereof is in the supernatant.
[0255] 29. The method according to any of the preceding embodiments, further comprising allowing flocculation to occur.
[0256] 30. The method according to any of the preceding embodiments, further comprising a step of obtaining the antibody or fragment thereof.
[0257] 31. The method according to any of the preceding embodiments, wherein separating in step b) comprises a solidliquid separation step selected from filtration, centrifugation, sedimentation, decantation; preferably filtration, more preferably in depth filtration.
[0258] 32. The method according to any of the preceding embodiments, wherein the supernatant is subjected to one or more of the following further purification steps: chromatography such as anion-exchange chromatography, cationexchange chromatography, hydrophobic-interaction chromatography, affinity chromatography; filtration such as micro-filtration, ultrafiltration; crystallization, precipitation for example by using ammonium sulfate and extraction for example by using multiphase systems.
[0259] 33. The method according to any of the preceding embodiments, wherein the antibody secreting cell culture is a mammalian cell culture; preferably a cell culture comprising Chinese ovary hamster (CHO) cells.
[0260] 34. The method according to any of the preceding embodiments, wherein the antibody or fragment thereof is a monoclonal antibody.
[0261] 35. The method according to the preceding embodiment, wherein the antibody is a murine antibody, a chimeric antibody, a humanized antibody, a human antibody or cNISTmAb.
[0262] 36. The method according to any of the preceding embodiments, wherein the monoclonal antibody is a humanized or a human monoclonal antibody.37. The method according to any of the preceding embodiments, wherein the monoclonal antibody is selected from the group consisting of Trastuzumab, Anti-Spike, Adalimumab, cNISTmAb.
[0263] 38. The method according to any of the preceding embodiments as described in step a)i), wherein the step of treating the cell culture with the partially hydrolyzed poly (N-vinyl amide) according to formula I comprises adding a sufficient amount of said partially hydrolyzed poly (N-vinyl amide) according to formula I, in particular at least 50 ppm.
[0264] 39. The method according to the preceding embodiment as described in step a)i), wherein the step of treating the cell culture with the partially hydrolyzed poly (N vinyl amide) according to formula I comprises adding at least 50 ppm, more particularly at least 100 ppm, even more particularly at least 300 ppm, still even more particularly at least 500 ppm of said partially hydrolyzed poly (N-vinyl amide) according to formula I to the cell culture.
[0265] 40. The method according to the preceding embodiment as described in step a)i), wherein the step of treating the cell culture with the partially hydrolyzed poly (N-vinyl amide) according to formula I comprises adding at most 5000 ppm, particularly at most 3000 ppm, more particularly at most 1500 ppm of said partially hydrolyzed poly (N-vinyl amide) according to formula I to the cell culture.
[0266] 41. The method according to any of the preceding embodiments as described in step a)i), wherein the step of treating the cell culture with the partially hydrolyzed poly (N-vinylamide) according to formula I comprises adding the partially hydrolyzed poly (N-vinylamide) according to formula I in a range of 300 ppm to 2000 ppm, more preferably in a range of 500 ppm to 1500 ppm to the cell culture.
[0267] 42. The method according to any of the preceding embodiments as described in step a)ii, wherein the step of treating the cell culture with the mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV comprises adding a sufficient amount of said mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV, in particular at least 50 ppm.
[0268] 43. The method according to the preceding embodiment as described in step a)ii), wherein the step of treating the cell culture with the mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV comprises adding at least 50 ppm, more particularly at least 100 ppm, even more particularly at least 300 ppm, still even more particularly at least 500 ppm of said mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV to the cell culture.44. The method according to the preceding embodiment as described in step a)ii), wherein the step of treating the cell culture with the mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV comprises adding at most 5000 ppm, particularly at most 3000 ppm, more particularly at most 1500 ppm of said mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV to the cell culture.
[0269] 45. The method according to any of the preceding embodiments as described in step a)ii), wherein the step of treating the cell culture with the mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV comprises adding the mixture of the partially hydrolyzed poly (N-vinyl amide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV in a range of 300 ppm to 2000 ppm, more preferably in a range of 500 ppm to 1500 ppm to the cell culture.
[0270] 46. The method according to any of the preceding embodiments as described in step a)iii), wherein the step of treating the cell culture with the labeled partially hydrolyzed poly (N-vinyl amide) according to formula V comprises adding a sufficient amount of said labeled partially hydrolyzed poly (N-vinyl amide) according to formula V, in particular at least 50 ppm.
[0271] 47. The method according to the preceding embodiment as described in step a)iii), wherein the step of treating the cell culture with the labeled partially hydrolyzed poly (N vinyl amide) according to formula V comprises adding at least 50 ppm, more particularly at least 100 ppm, even more particularly at least 300 ppm, still even more particularly at least 500 ppm of said labeled partially hydrolyzed poly (N-vinyl amide) according to formula V to the cell culture.
[0272] 48. The method according to the preceding embodiment as described in step a)iii), wherein the step of treating the cell culture with the labeled partially hydrolyzed poly (N-vinyl amide) according to formula V comprises adding at most 5000 ppm, particularly at most 3000 ppm, more particularly at most 1500 ppm of said labeled partially hydrolyzed poly (N-vinyl amide) according to formula V to the cell culture.
[0273] 49. The method according to any of the preceding embodiments as described in step a)iii), wherein the step of treating the cell culture with the labeled partially hydrolyzed poly (N-vinylamide) according to formula V comprises adding the labeled partially hydrolyzed poly (N-vinylamide) according to formula V in a range of 300 ppm to 2000 ppm, more preferably in a range of 500 ppm to 1500 ppm to the cell culture.
[0274] 50. The method according to any of the preceding embodiments, further comprising a step of adjusting the pH to a value between pH 5.0 and 7.0, preferably prior to or simultaneous with the treating in step a).51. An antibody or fragment thereof obtained by or obtainable by the method according to any of the preceding embodiments.
[0275] 52. A composition comprising the antibody according to the preceding embodiment, preferably a semi purified composition comprising the antibody according to the preceding embodiment.
[0276] 53. The composition according to the preceding embodiment, wherein the composition consists of the supernatant obtained by the method according to any of the preceding embodiments.
[0277] 54. The composition according to the two preceding embodiments, wherein the composition comprises at most 5 %, preferably at most 2 % of residual DNA and / or low levels of one or more of the following host cell proteins (HCPs): 78 kDA glucose regulated protein (GRP78, BiP), Clusterin, Cathepsin B, procollagen-lysin2-oxoglutarate 5-deoxy-genaose 1 (PLOD1).
[0278] 55. The composition according to the preceding embodiment 54, wherein low levels of host cell proteins refer to at least 10 %, preferably to at least 20 %, more preferably to at least 30 % reduction in the host cell protein content as determined by ELISA in comparison to an untreated sample.
[0279] 56. The composition according to the preceding embodiment 54, wherein the % of residual DNA in the preparation is determined by PicoGreen assay.
[0280] 57. Use of (I) a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof, a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof, or a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof for antibody purification,
[0281] wherein formula I is
[0282]
[0283] formula I
[0284] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; wherein formula IV is
[0285]
[0286] formula IV,
[0287] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label;
[0288] wherein formula V is:
[0289]
[0290] formula V,
[0291] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label.
[0292] 58. The use according to embodiment 57, wherein the partially hydrolyzed poly (N-vinylamide) comprises at most 90 mol-% of monomer units according to formula II
[0293]
[0294] R2
[0295] formuia IIand
[0296] at least 10 mol-% monomer units according to formula III:
[0297]
[0298] NRXH
[0299] formula III
[0300] wherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5; and wherein Rx= H, CH3, or C2H5; preferably Rx= H.59. The use according to embodiment 57, wherein the labeled partially hydrolyzed poly (N-vinylamide) of formula IV comprises at most 90 mol-% of monomer units according to formula II
[0301]
[0302] R2
[0303] formula 11and
[0304] at least 10 mol-% monomer units according to formula III:
[0305]
[0306] NRXH
[0307] formula III
[0308] and at least 0.00005 mol % of monomer units according to formula VI:
[0309]
[0310] NRXR3
[0311] formula VI
[0312] wherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5; and wherein Rx= H, CH3, or C2H5; preferably Rx= H, and wherein Rs.= a label, preferably R3 = a fluorescent label, more preferably Rs= fluorescein label.
[0313] 60. The use according to embodiment 57, wherein the labeled partially hydrolyzed poly (N-vinylamide) of formula V comprises at most 90 mol-% of monomer units according to formula II
[0314]
[0315] R2
[0316] formula II andat least 10 mol-% monomer units according to formula III:
[0317]
[0318] NRXH
[0319] formula III
[0320] and at least 0.00001 mol % of monomer units according to formula VI:
[0321]
[0322] NRXR3
[0323] formula VI,
[0324] wherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5; and wherein Rx= H, CH3, or C2H5; preferably Rx= H, and wherein Rs.= a label, preferably R3 = a fluorescent label, more preferably Rs= fluorescein label.
[0325] 61. The use according to the preceding embodiment, wherein the purification is performed as in any of the preceding method embodiments.
[0326] 62. A composition comprising:
[0327] - (I) a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof:
[0328]
[0329] formula I
[0330] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl;
[0331] (II) a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof:
[0332]
[0333] formula IV,
[0334] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label;
[0335] or
[0336] (iii) a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof:
[0337]
[0338] formula V,
[0339] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label;
[0340] cell culture cells, and
[0341] a shear protectant.
[0342] 63. A labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof
[0343]
[0344] formula IV,
[0345] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; in particular as described in any of the preceding embodiments.
[0346] 64. A labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof
[0347]
[0348] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00001 mol % of the monomer units R1 = R3 = a label; in particular a fluorescent label; in particular as described in any of the preceding embodiments.
[0349] 65. A mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof
[0350]
[0351] NRXR1
[0352] formula I
[0353] wherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof :
[0354]
[0355] NRXR1
[0356] formula IV,
[0357] wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00005 mol % of the monomer units R1 = R3 = a label; in particular a fluorescent label; in particular as described in any of the preceding embodiments.FIGURES
[0358] Figure 1 Performance of certain partially hydrolyzed poly (N-vinylformamides) in view of (A) turbidity, (B) antibody recovery, (C) residual HOP and (D) removal of DNA.
[0359] Figure 2 Performance of permanently charged variants of partially hydrolyzed poly (N-vinylformamides) in view of (A) turbidity, (B) removal of DNA and (C) residual HOP.
[0360] Figure 3 Performance of the partially hydrolyzed poly (N-vinylformamide) X9 concerning four different cell cultures, each producing a specific monoclonal antibody, in view of (A) turbidity, (B) antibody recovery, (C) removal of DNA and (D) residual HOP.
[0361] Figure 4 Reduction in selected high-risk HCPs after flocculation concerning a cell culture producing Trastuzumab.
[0362] Figure 5 Reduction in selected high-risk HCPs after flocculation concerning a cell culture producing Anti-Spike.
[0363] Figure 6 Chromatographs of protein A chromatography and cation exchange chromatography of non-flocculated control and flocculated samples with partially hydrolyzed poly (N-vinylformamide) X9 or pDADMAC.
[0364] Figure 7 Calibration curves from 0.1-5 ppm partially hydrolyzed poly (N-vinylformamide), degree of hydrolysis 50% (A,B) and 95% (C) with a MW of approx. 550000 g / mol with varying degrees of FITC-labeling and mixtures with unlabeled polymer in water.
[0365] Figure 8 Performance of partially hydrolyzed poly (N-vinylformamide), degree of hydrolysis 50%, MW approx..
[0366] 550000 g / mol (E1) and labeled variant L1 in view of (A) turbidity, (B) antibody recovery, (C) DNA removal and (D) HCP reduction.
[0367] Figure 9 Performance in E. coll lysate of partially hydrolyzed poly (N-vinylformamides) with a theoretical MW of 55000 g / mol and a degree of hydrolysis of 50% in view of (A) DNA removal, (C) endotoxin removal and (E) residual HCPs at pH 5, 6 and 7, respectively. Right column represents (B) DNA removal, (D) endotoxin removal and (F) residual HCPs at pH 7 in comparison to pDADMACEXAMPLES
[0368] The flocculation in the examples below were performed with mammalian cell cultures producing respective antibodies after stopping the cultivation (= harvest) at a cell viability between 55-85%, unless stated otherwise. The performance of the partially hydrolyzed poly (N-vinylamides), the labeled partially hydrolyzed poly (N-vinylamides) and mixtures thereof according to the invention were compared to the performance of non-flocculated control (s) and / or the performance of the known flocculant polydiallyldimethylammonium chloride (pDADMAC) supplied by Millipore. The performance in flocculation was characterized by antibody yield and / or DNA removal and / or host cell protein (HOP) removal and / or turbidity:
[0369] (In the following the term "cultivation supernatant” is used for a sample which is obtained from a mammalian cell culture after stopping the cultivation, adding a flocculant followed by centrifugation and separating the supernatant; in case of the non-flocculated controls the step of adding a flocculant is not carried out).
[0370] Antibody concentration was determined by analytical protein A chromatography on a Dionex UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, USA) with Chromeleon™ 7 software (Thermo Fisher Scientific, Waltham, USA). The system was set to a flow rate of 2.5 mL / min. The cultivation supernatant was filtered over a filter with 0.22 pm pore diameter and 50 pl of the resulting filtrate was loaded on a POROS A 20-pm column (2.1 x 30 mm), 0.1 ml column volume (Thermo Fisher Scientific, Waltham, USA, Art.Nr. : 2100100). The column was equilibrated with 10 column volumes of mobile phase A consisting of 50 mM phosphate buffer with 150 mM NaCI pH 7.0, eluted with a step gradient with 20 column volumes of 100% 100 mM mobile phase B consisting of glycine buffer, pH 2.5, and re-equilibrated with 30 column volumes of mobile phase A. The absorbance at 280 nm was used for antibody quantification. A protein A chromatography purified lgG1 was used as calibration standard (expected retention time: 0.9 min).
[0371] DNA was detected and quantified using the Quant-iT PicoGreen dsDNA assay Kit (Thermo Fisher Scientific, Waltham; USA; Art. Nr.: P7589).
[0372] HOP quantification: First, the cultivation supernatant was pre-treated using cation exchange chromatography in batch mode to avoid interactions of residual flocculant with the HOP ELISA Kit to be used in the determination. Therefore, 50 pl cultivation supernatant was diluted with 4 pl of a 4 mol / L sodium chloride solution (the so obtained mixture has a concentration of 300 mmol NaCI). Afterwards, 10 pL of a 50% slurry of cation exchange resin, which was obtained by resuspending, decanting and diluting the resin ESHMUNO CP-FT suspension (Merck, Darmstadt, Germany; Art.Nr.: 1200930010) in 50 mM phosphate buffer pH5,5, was added. The obtained mixture was incubated for 1 hour at 22°C at 800 rpm using Thermomix comfort 5355 (Eppendorf, Hamburg, Germany). After centrifugation the supernatant was separated and the HCP content in the supernatant was quantified using the CHO HCP ELISA Kit, 3G (F550-1) (Cygnus Technologies, Southport, USA; Art.Nr.: F550-1).Turbidity in Nephelometric Turbidity Unit (NTU) was determined with 9 ml of the cultivation supernatant by a 2100Q Portable Turbidimeter (Hach, Loveland, USA).
[0373] Deviations are presented as mean ± range for duplicates (n =2) and mean ± standard deviations for triplicates (n=3).
[0374] General procedure for the preparation of respective cell cultures:
[0375] As mammalian host cell lines a CHO-S producing Trastuzumab cell line, or a CHO-GS producing Anti-Spike cell line (developed by Icosagen AS (Tallinn, Estonia)), or a CHO-K1 producing Adalimumab cell line, or a CHO-K1 producing cNISTmAb cell line (National Institute of Standards and Technology (NIST) (Research Grade Test Material 10197)) were used.
[0376] Cells were cultured in disposable vented Erlenmeyer shake flasks (VWR, Radnor, USA; Art. Nr. : 734-1887 or 734-1889) or using the DASGIP Bioblock system (Eppendorf, Hamburg, Germany; 76DG04CCBB). As basal medium, the commercially available medium HyClone™ ActiPRO™ (Cytiva, Uppsala, Sweden) was used. The basal medium was supplemented with 8 mM glutamine for Trastuzumab.
[0377] Cryovials of 1 mL with 107cells / mL were stored in the vapor phase of liquid nitrogen and thawed at room temperature. After thawing, 10 mL of freshly prepared basal medium was added, and cells were centrifuged at 200 g for 5 min at 20°C. The supernatant was discarded, and cells were resuspended in 25 mL of fresh basal medium. Cell cultures were grown at 37°C, 8% CO2, 120 rpm in a CO2 incubator shaker New Brunswick S411 with 2.5 cm orbit (Eppendorf, Hamburg, Germany; Art. Nr.: S411230011) and maintained between a cell count of 0.5 and 4x106cells / mL (passaged every 3 or 4 days). Cell viability and cell count was measured using Vi-CELL XR Cell Counter (Beckmann Coulter, Brea, USA, Art. Nr.: 383556). Cell Counter was supplied with Trypan Blue (Merck, Darmstadt, Germany, Art. Nr. : T8154-100ML) to allow cell staining and determination of cell viability.
[0378] On the day of inoculation, cells were centrifuged at 200 g for 5 min at 20°C and were resuspended in 10% spent media and 90% fresh media at a seeding cell density of 7.5 x 105cells / mL. The fed-batch experiments were carried out either in a 500 mL disposable vented Erlenmeyer shake flasks (Art. Nr. : 734-1887, starting volume 150 mL), 1000 mL disposable vented Erlenmeyer shake flasks (Art. Nr. : 734-1889, starting volume 400 mL), a 1800 mL DASGIP Bioblock system (Eppendorf, Hamburg, Germany; 76DG04CCBB, starting volume 1000 mL) or a 3000 mL BioFlo 320 system (Eppendorf, Hamburg, Germany ; M1379-0102, starting volume 3000 mL). The DASGIP bioblock system consisted of a glass bioreactor (Eppendorf, Hamburg, Germany; 76SR1500CDLS) with a 3-Blade Impeller, 30° pitch (Art. Nr.: 78532236). The BioFlo 320 system consisted of a glass bioreactor (Eppendorf, Hamburg, Germany; MISTO-OSH) with a built-in 3-Blade Impeller, 30° pitch. In the bioreactors, the cultivation conditions were set to a constant pH of 6.9 ± 0.05, a constant dissolved oxygen rate (DO) of 40 % and a stirrer speed starting at 80 rpm gradually increasing to 250 rpm over the course of 9 days to maintain the DO (VisiFerm DO EOS 325 DO probe; Hamilton, Reno, USA; Art. Nr. :234666-241 ). The pH was controlled by CO2 addition in the sparger gas flow as acid and the addition of 7.5 % sodium bicarbonate as base. The DO was controlled by the proportion of oxygen in the sparger gas flow, the gas flow rate and the stirrer speed. In bioreactors, Antifoam C Emulsion (Sigma Aldrich, Darmstadt, Germany; Art. Nr. : A8011) was added dropwise on demand to control foam levels.Feeding of cells was performed by daily addition of HyClone™ Cell Boost™ 7a (Cytiva, Uppsala, Sweden) at 2% of the batch volume and HyClone™ Cell Boost™ 7b (Cytiva, Uppsala, Sweden) at 0.2% of the batch volume starting from day 3 on. On day 5 of the fed-batch cultivation the temperature was reduced from 37°C to 32°C. Viability and cell count was measured daily and the harvest criteria was a drop of viability below 70%. The so obtained cell cultures were used in the Examples.
[0379] General procedure of the preparation of partially hydrolyzed poly (N-vinylamides)
[0380] A. Step A: Synthesis of poly N-vinylamides
[0381] The production of poly (N-vinylamides) typically occurs through free radical solution polymerization in water, maintaining a pH of 6-7 with a phosphate buffer and using a water-soluble azo initiator as the radical source.
[0382] Preferably, the azo compounds that are specified for this purpose in DE-OS 1495692 are used for the polymerization.
[0383] The quantity of initiator, reaction temperature, and the concentration of monomer and radicals, which are controlled by their respective feeding rates, determine the molecular weight of the resulting polymer.
[0384] For achieving higher K-values, a batch process is preferred, while for medium and lower K-values, a continuous feed process is favoured. In the batch process, water and the monomer are initially charged in the reactor, and the initiator is added. If viscosity becomes too high, water can be added to maintain a manageable mixture. In the continuous feed method, water is charged in the reactor first, followed by the addition of the monomer and the initiator, potentially diluted in water.
[0385] General Procedure 1 for the production of poly (N-vinylformamide) with a K-value of 90
[0386] Under a nitrogen inert atmosphere deionized water is adjusted to a pH of 6.2-6.5 with a mixture of 75% phosphoric acid and 25% sodium hydroxide, heated to around 70°C. A vacuum of approximately 350 mbar is applied, and N-vinylformamide is dosed at a rate of about 3 g / min to achieve a final concentration of 20wt%. Simultaneously, a diluted solution of the initiator Wako V50 (2,2'-Azobis(2-methylpropionamidin)dihydrochloride; Fujifiilm Wako Chemicals Europe GmbH; Cas-No.2997-92-4) is introduced at a concentration of 0.5wt% relative to the monomer at a rate of approximately 0.5 g / min. After dosing is complete, the mixture is diluted with deionized water as needed and polymerized for an additional 4 hours at 70°C. The polymer solution obtained has a K-value of 90 when measured at 25°C as a 0.5wt% solution in deionized water.
[0387] Laboratory Example 1 :
[0388] In a 2L reactor, 895.5 g of deionized water, 2.58 g of 75% phosphoric acid, and 4.0 g of 25% sodium hydroxide are mixed, adjusting the amounts if necessary to obtain a pH between 6.2 and 6.5. The mixture is heated to 72°C, and a vacuum of 350 mbar is established. N-vinylformamide is dosed over 1 hour and 15 minutes, followed by a 2wt% solution of Wako V50 over 2 hours. After the initiator dosing, an additional 200 g of deionized water is added over 30minutes, and the mixture is polymerized for 4 more hours at 72°C. The resulting polymer solution has a K-value of 91.1.
[0389] B. Step B: partial hydrolysis of poly (N-vinylamides)
[0390] General Procedure 2 for the basic hydrolysis of poly N-vinylformamides.
[0391] An aqueous solution of the poly N-vinylformamide is treated with 2.6 wt% sodium bisulfite (based on polymer content) in form of a 40wt% aqueous solution and heated to 80°C. Then, 53 wt% sodium hydroxide (based on polymer content) in form of a 25wt% solution is added, and the mixture is stirred for 6 hours at 80°C. The pH is adjusted to 7-8 with hydrochloric acid, resulting in a polymer with a degree of hydrolysis of 50%, which can be measured by polyelectrolyte titration.
[0392] Furthermore, solvolysis conditions can be chosen as mentioned and described in EP 71050.
[0393] Laboratory Example 2:
[0394] The polymer solution obtained in Laboratory Example 1 is treated with 17 g of a 40wt% sodium bisulfite solution and heated to 80°C. Within 10 minutes, 578.6 g of a 40wt% sodium hydroxide solution is continuously added, and the mixture is stirred for 6 hours at 80°C, yielding a polymer with a degree of hydrolysis of 89%, measured by polyelectrolyte titration.
[0395] The partially hydrolyzed poly (N-vinylformamides) X1 to X10 and X11 to X13 given in Table 2, are prepared accordingly.
[0396] C: Optional Step C Preparation of a permanently charged partially hydrolyzed poly (N-vinylformamide)
[0397] General Procedure 3 for the preparation of permanently charged modifications
[0398] A solution of a (partially) hydrolyzed poly (N-vinylformamide) is adjusted to a pH of about 10 with sodium hydroxide. At 80°C, a corresponding amount of 3-acrylamidopropyltrimethylammonium chloride (compound A) is dosed over 2 hours, followed by several hours of keeping the mixture at that temperature while stirring. The conversion is determined from the dried polymer sample using 1 H-NMR (in D2O) based on the remaining density of acrylic double bonds.
[0399] Laboratory Example 3:
[0400] 100 g of an aqueous solution of a partially hydrolyzed poly (N-vinylformamide) having a K-value 90 and a hydrolysis degree of 50, wherein the polymer content is 13 wt%, is placed in a 250 ml flask and adjusted to pH 10 with 7.08 g of a 10wt% sodium hydroxide solution. Under stirring at 80°C, 26.66 g of 3-acrylamidopropyltrimethylammonium chloride (compound A) is added over 2 hours, and the reaction mixture is stirred for an additional 28 hours at 80°C. The mixture is then cooled, and a dried sample is characterized using1H-NMR in D2O as the solvent.The partially hydrolyzed poly (N-vinylformamides) X10a and X1 Ob given in Table 2, are prepared accordingly. In Table 2, the percentage of free amino-functions of the partially hydrolyzed poly (N-vinylformamide) (raw material) coupled with compound A is given in column 5.
[0401] Table 2: Overview of different partially hydrolyzed poly (N-vinylformamides) (Ri= CHO, Rx= H for X1 to X10 and X11 to X13) (in salt form)
[0402] Free amino functions coupled Sample no. Theoret. MW [g / mol] Theoret. K-value Degree of hydrolysis [%]
[0403] with compound A [%] X1 80000 45 0 0
[0404] X2 80000 45 10 0
[0405] X3 80000 45 30 0
[0406] X4 80000 45 50 0
[0407] X5 80000 45 95 0
[0408] X6 550000 90 0 0
[0409] X7 550000 90 10 0
[0410] X8 550000 90 30 0
[0411] X9 550000 90 50 0
[0412] X10 550000 90 95 0
[0413] X10a 760000 Not determined 95 10
[0414] X10b 3000000 Not determined 95 100
[0415] X11 1400000 126 0 0
[0416] X12 1400000 126 10 0
[0417] X13 1400000 126 25 0
[0418]
[0419] In the following Examples all partially hydrolyzed poly (N-vinylformamides) were tested in their hydrochloric acid salt form.
[0420] Example 1 Effect of molecular weight, permanent positive charge and degree of hydrolysis of the partially hydrolyzed poly N-vinylformamides on flocculation performance
[0421] CHO cells producing either Trastuzumab or Anti-Spike were harvested at a cell viability of approximately 65%-70%. The obtained cell cultures were flocculated at 555 ppm of partially hydrolyzed poly (N-vinylformamide) polymers (calculated on the pure polymer, excluding salt content) with different molecular weight, degree of hydrolysis (n=3) and degree of permanent charge (n=2) to identify an optimum for performance.All partially hydrolyzed poly N-vinylformamides were tested in their hydrochloric acid salt form. As a control a cell culture was flocculated by 750 ppm pDADMAC. Figure 1 represents the clarification performance for different partially hydrolyzed poly (N-vinylformamides) with different molecular weights and degree of hydrolysis. While the molecular weight did not show a distinct effect in any of the tested parameters, a degree of hydrolysis of > 25% improved DNA removal and reduction in turbidity. No effect on antibody yield was detected for any of the tested flocculants. HOP concentration could be most effectively reduced with partially hydrolyzed poly (N-vinylformamides) with a degree of hydrolysis of more than 30% with an optimum at 50% irrespective of molecular weight. Introduction of permanent charge did not improve clarification performance beyond degree of hydrolysis (Figure 2).
[0422] Example 2 Robust clarification with improved IgG recovery, DNA and HOP removal in four antibody models
[0423] To determine robustness of flocculation performance four different cell cultures, each producing a distinct antibody, were harvested at a cell viability of approximately 60%-80% (n = 2). Each cell culture was flocculated with 555 ppm of the partially hydrolyzed poly (N-vinylformamide) X9 (calculated on the pure polymer, excluding salt content; corresponding to 1000 ppm solid content including salts) or 750 ppm pDADMAC and incubated for 20 min. All obtained mixtures were centrifuged at 100 g for 10 min. Figure 3 represents the data for antibody yield, DNA and HCP removal and turbidity. In general, flocculation reduced turbidity below 20 NTU and DNA to approximately 1% without reducing antibody yield in any of the tested models. However, the partially hydrolyzed poly (N-vinylformamide) X9 reduced the HCP concentration by at least 20% up to 50% superior to pDADMAC depending on the antibody model. Minimizing the HCP level already early in the process reduces the burden for further purification steps improving product quality.
[0424] Example 3 Removal of high-risk HCP
[0425] High-risk HCPs are critical for the quality and safety of monoclonal antibody products as they can lead to immunogenic reactions in patients or impact product stability.
[0426] To determine the flocculation performance in view of such high risk HPCs a Trastuzumab producing CHO-S cell line and an Anti-Spike producing CHO-GS cell line, were harvested at a cell viability of approximately 55% and 70%, respectively (n=2). Each cell culture was flocculated with 555 ppm of the partially hydrolyzed poly (N-vinylformamide) X9 (calculated on the pure polymer, excluding salt content; corresponding to1000 ppm solid content including salts) or 750 ppm pDADMAC and incubated for 20 min. After centrifugation and separation, the obtained cultivation supernatant was subjected to protein digestion and peptide clean-up using a S-trapTM micro spin colums kit (ProtiFi LLC, Farmindale, NY, USA). In brief, 15 piL of the cultivation supernatant were mixed with 15 piL of a buffer (10% sodium dodecyl sulfate (SDS), 50 mM Tris HCI; pH 8.5) and sonicated in a bath sonicator for 5 min. Reduction was conducted by adding dithiothreitol (DTT) to a final concentration of 7.5 mM and incubating at 56 °C for 40 min. S-Alkyla-tion was performed by addition of iodoacetic amide (IAA) to a final concentration of 15 mM and incubation in the darkat room temperature for 30 min. Thereafter, phosphoric acid (final concentration of about 2.5%) and washing / binding buffer (triethylammonium bicarbonate (TEAB), 100 mM (final) in 90% methanol; 6X the total volume of sample) were added before the sample was trapped on the S-Trap™ micro spin column. First the column was washed 4 times with the washing / binding buffer. Digestion was carried out overnight with trypsin platinum (Promega) at a 1:10 weight to weight ratio in 20 pL 50 mM ammonium bicarbonate (ABC). Elution of digested proteins / peptides was mediated by centrifuging for 1 min at 4,000 ref after applying 40 L ABC to the S-Trap micro spin column. Within two steps 40 pL 0.2% formic acid (FA) and 40 pL of 0.2% FA in 50% acetonitrile (ACN) were loaded onto the column and centrifuged at same conditions. The flow through was vacuum-dried and taken up in 0.1% FA in water (= A) for mass spectrometry measurement.
[0427] The digested samples were loaded on a nanoEase C18 column (nanoEase M / Z HSS T3 Column, 100A, 1.8 pm, 300 pm X 150 mm, Waters). A gradient from 1% B (B: 80% ACN, 0.1% FA) to 40% B in 75 min was applied, followed by a 10 min gradient from 40% B to 95% B that facilitates elution of large peptides, at a flow rate of 6 pL / min (Solvent A: 0.1% FA in water). Detection was performed with an Orbitrap MS (Exploris 480, Thermo) equipped with the standard H-ESI source in positive ion, DDA mode (= switching to MSMS mode for eluting peaks). MS-scans were recorded (range: 350-1200 Da) and the 20 highest peaks were selected for fragmentation. Instrument calibration was performed using Pierce FlexMix Calibration Solution (Thermo Scientific). The analysis files were analysed using PEAKS, which is suitable for performing MS / MS ion searches. The files were searched against a CHO database.
[0428] HCP concentration was compared to non-flocculated control. Compared to pDADMAC the partially hydrolyzed poly (N-vinylformamide) X9 led to superior reduction in high-risk HCPs in 12 out of 14 for Trastuzumab (Figure 4) and in 9 out of 11 for Anti-Spike (Figure 5). Remarkably, a superior reduction in high risk host cell proteins with high immunogenic potential is seen in Figure 4 and Figure 5, as the tested potentially immunogenic host cell proteins are highly reduced, including Protein S100-A6 (S10A6), Clusterin (CLU), Procollagen-lysine 2-oxoglutarate 5-deoxygenase_1 (PLOD1) (see Table 1).
[0429] Example 4 Compatibility of partially hydrolyzed poly N-vinylformamides with chromatography resins
[0430] To avoid loss of antibodies during purification, interactions of residual polymer with chromatography resins was evaluated. A cultivation supernatant obtained from a cell culture of a CHO-K1 producing cNISTmAb cell line where subjected a preparative protein A affinity chromatography followed by a preparative cation exchange chromatography (CEX). Both chromatographic steps were conducted with a chromatographic workstation AKTA Avant 150 coupled with an in-built fraction collector (Cytiva, Uppsala, Sweden). Protein A affinity chromatography was performed on MabSelect PrismA resin (Cytiva) packed into a 0.5x10 cm column in a Tricorn 5 / 100 column housing (Cytiva). The equilibration and elution buffer were 1x PBS at pH 7.4 and 25 mM citrate buffer at pH 3.2, respectively. The eluate was collected using the fractionating system and was neutralized and simultaneously preconditioned by 1:2 dilution using CEX equilibration buffer (50 mM acetate at pH 5.5). CEX resin Capto S ImpAct (Cytiva) was custom prepackedin a 0.5x2.5 cm OPUS MiniChrom housing (Repligen, Waltham, USA). The elution buffer was 50 mM acetate + 1000 mM sodium chloride at pH 5.5. In Figure 6 exemplary chromatographs of purification via protein A affinity chromatography and CEXfor the cNISTmAb model are shown. Flocculation with pDADMAC results in a protein breakthrough during load phase in both chromatographic steps reducing the antibody yield. In contrast, the flocculation with the partially hydrolyzed poly (N-vinylformamide) X9 shows excellent compatibility with both resins.
[0431] Example 5 Production of Anti-Spike in small-scale bioreactors with subsequent chromatographic purification
[0432] To further demonstrate the efficient clarification and removal of HCPs experiments in small scale bioreactors with a cell culture of a CHO-GS producing Anti-Spike cell line were conducted. Cells culture was harvested at 85% viability yielding in a HCP concentration of approximately 430 pig / mL and an Anti-Spike titer of 1.4 g / L. In each case the cell culture was flocculated with 555 ppm of the partially hydrolyzed poly (N-vinylformamide) X9 (calculated on the pure polymer, excluding salt content; corresponding to 1000 ppm solid content including salts) or 750 ppm pDADMAC and incubated for 20 min. All mixtures were centrifugated at 100 g for 10 min. (In case of the non-flocculated controls the step of adding a flocculant is not carried out). Downstream purification consisted of protein A chromatography followed by cation exchange chromatography (CEX). All chromatographic steps were conducted with a chromatographic workstation AKTA Pure 25 coupled with a fraction collector (Cytiva, Uppsala, Sweden). Protein A affinity chromatography was performed on MabSelect PrismA resin (Cytiva), custom prepacked in a 0.8x10 cm OPUS MiniChrom column. The equilibration and elution buffer were 1x PBS at pH 7.4 and 25 mM citrate buffer at pH 3.2, respectively. The eluate was collected using the fractionating system and was neutralized and simultaneously preconditioned by 1 :2 dilution using CEX equilibration buffer (50 mM acetate at pH 5.5). CEX resin Capto S ImpAct (Cytiva) was custom prepacked in a 0.8x5 cm OPUS MiniChrom housing (Repligen, Waltham, USA). The elution buffer was 50 mM acetate + 1000 mM sodium chloride at pH 5.5.
[0433] Flocculation decreased the HCP load for downstream purification with superior reduction of HCPs when the partially hydrolyzed poly (N-vinylformamide) X9 is used compared to pDADMAC and compared to the non-flocculated control. This effect was persistent in protein A affinity chromatography and CEX polish reducing the initial HCP burden as well as improving the effectiveness in removal during protein A affinity chromatography and CEX purification. HCP concentration after CEX was 1,055 ppm for non-flocculated control, 203 ppm for the partially hydrolyzed poly (N-vi-nylformamide) X9 and 3,849 ppm for pDADMAC. Besides that flocculation with pDADMAC reduced Anti-Spike yield by approximately 50% during CEX polish.
[0434] Table 3: Overview of HCP load after Protein A capture and after CEX polish
[0435] Protein A capture (Bind / elute mode) CEX polish (Bind / elute mode) Antibody yield HCP Antibody yield HCP
[0436] (mg) (pg; [ppm]) (mg) (pg [ppm]) Non-flocculated control Load 224 62,743 208 562
[0437] [280,165] [2,700]
[0438]
[0439] Eluate 206 557 155 163
[0440] [2,700] [1,055] partially hydrolyzed poly Load 229 46,263 195 80
[0441] (N-vinylformamide) X9 [201,930]
[0414]
[0442] Eluate 202 84 199 40
[0443]
[0414]
[0203] pDADMAC Load 245 71,399 228 1,683
[0444] [292,877] [7,383] Eluate 255 1,869 118 453
[0445] [7,381] [3,849]
[0446]
[0447] Example 6 Impact of flocculation on antibody functionality
[0448] To confirm that flocculation with the partially hydrolyzed poly (N-vinylformamide) X9 does not impact antibody functionality the binding kinetics of the target antibody was determined by surface plasmon resonance (SPR).
[0449] SPR measurements were performed using the Biacore T200 system (Cytiva, Sweden) and a Series S Sensor Chip CM5 (Cytiva). This capture kit (Cytiva) has been used to immobilize Anti-His antibody on the chip surface by amine coupling on flow cells 3 and 4. Flow cell 2 has been amine coupled with recombinant human FcRN receptor (R&D Systems, USA) at a level of 600 response units, while flow cell 1 has been blank immobilized.
[0450] For antigen binding either a His-tagged Her2 protein (Acrobiotech, USA, CA) at a concentration of 50 pig / mL or a His-tagged trimeric Spike-protein (produced in house) at a concentration of 3 pig / mL has been captured on flow cell 4 via the coupled anti-His antibody using a flow rate of 10 piL / min and a contact time of 25 s, while flow cell 3 was treated as blank. Multi-cycle kinetics were measured by injection of Trastuzumab (concentrations between 0.3125 nM and 5.0 nM) or Anti-Spike (concentrations between 18.75 nM and 600 nM) at a flow rate of 30 piL / min and a contact time of 700 s or 500 s. After desorption with PBS with 0.05% tween and 0.1 mg / mL BSA at pH 7.4 for 400 s the chip was regenerated for 30 s at 30 piL / min with 100 mM glycine at pH 1.5 (Cytiva).
[0451] Binding to the FcRN receptor was simulated as follows: Multi-cycle kinetics were measured by binding of Trastuzumab and Anti-Spike, respectively, to the amine coupled FcRN receptor in flow cell 2 and the blank immobilized flow cell 1. Concentrations between 0.06125 nM and 1.0 nM at a flow rate of 30 piL / min and a contact time of 90 s were injected. After desorption with PBS with 0.05% tween at pH 6.0 for 60 s the chip was regenerated for 60 s at 30 piL / min with PBS with 0.05% tween at pH 7.4 (Cytiva). The data was fitted by using the 1:1 binding model in the Biacore T200 evaluation software (Cytiva).
[0452] After flocculation with 555 ppm of the partially hydrolyzed poly (N-vinylformamide) X9 (calculated on the pure polymer, excluding salt content; corresponding to 1000 ppm solid content including salts) partially hydrolyzed poly (N-vinylformamide) X9, the fitted KD from antigen and FcRN binding was not altered for Trastuzumab and Anti-Spike compared to non-flocculated control (Table 4). Therefore, no impact on antibody functionality by flocculation with partially hydrolyzed poly (N-vinylformamide) X9 was observed.Table 4: Impact of flocculation with partially hydrolyzed poly N-vinylformamide X9 on antibody binding kinetics compared to non-flocculated control
[0453] Antigen binding KD (nM) FcRN binding KD (nM)
[0454] Non-flocculated + partially hydrolyzed poly Non-flocculated + partially hydrolyzed poly (Nvinylformamide) X9 (N-vinylformamide) X9 Trastuzumab < 0.05 < 0.05 8.9 7.3
[0455] Anti-Spike < 0.1 < 0.1 2.4 2.8
[0456]
[0457] Example 7 Synthesis of labeled partially hydrolyzed poly (N-vinylamides)
[0458] Synthesis of partially hydrolyzed poly (N-vinylamides) labeled with fluorescein isothiocyanate (FITC) according to formula IV or V (R3 = CS-fluorescenyl with fluorescenyl = 6-amino-3',6'-dihydroxy-spiro[isobenzofuran-3,9'-xanthene]-1-one) (Table 5)
[0459] Example 7a) Synthesis of Sample L9:
[0460] To a stirred solution of 115.81g partially hydrolyzed poly (N-vinylformamide), degree of hydrolysis 95%, MW approx.
[0461] 550000 g / mol (desalted prior to use by ultrafiltration), solid content 6.75% in water (E2), a solution of 0.08 g Fluores-cein-5-isothiocyanat (FITC), dissolved in 2.16 g of dimethyl sulfoxide, was added and the mixture was stirred at room temperature for 6.5h.
[0462] The orange-colored polymer solution obtained, was subjected to a dialysis in deionized water with a molecular weight cut-off of 3500 g / mol for 6 days with a daily exchange of the water phase. The permeate was filtered through a 0.45pm syringe filter prior to measurement of the fluorescence. No fluorescence could be detected for the collected permeate, hence the fluorescein derivative is covalently bound to the polymer and cannot be washed out.
[0463] Example 7b) Synthesis of L1, L2, L3, L4 respectively:
[0464] To a stirred solution of 120g partially hydrolyzed poly (N-vinylformamide), degree of hydrolysis 50%, MW approx. 550000 g / mol, solid content 18% (E1), adjusted to pH 11 by addition of 10% sodium hydroxide solution, a solution of 4.7 mg or 2.35 mg or 0.47 mg or 0.047 mg Fluorescein-5-isothiocyanat (FITC), dissolved in 5.02 g or 4.33 g or 0.867 g or 0.087 g of dimethyl sulfoxide, was added over a period of 1h at ambient temperature to obtain labeling degrees of 0.0054 mol%, 0.0027 mol%, 0.00054 mol% or 0.000054 mol%. in the labeled polymer. The mixture was stirred for additional 3.5h. The pH was adjusted to 8 by addition of 30% hydrochloric acid solution. A clear, yellow solution was obtained and used without further purification.
[0465] Example 7c) Preparation of L5, L6, L7, L8 respectivelyL1 as obtained in Example 7b was mixed with the partially hydrolyzed poly (N-vinylformamide), degree of hydrolysis 50%, MW approx. 550000 g / mol, solid content 18% (E1), in a ratio of 9 : 1, 1 : 1, 1 : 9, 1 : 99 to obtain Samples L5, L6, L7 and L8 respectively.
[0466] Example 7d) Preparation of L10, L11, L12, L13 respectively
[0467] L9 as obtained in Example 7a was mixed with the partially hydrolyzed poly (N-vinylformamide), degree of hydrolysis 95%, MW approx. 550000 g / mol, solid content 6,75 % (E2), in a ratio of 9 : 1, 1 : 1, 1 : 9, 1 : 99 to obtain Samples L10, L11, L12 and L13 respectively.
[0468] Table 5: Overview of cationic polymers tagged using FITC and mixtures with unlabeled polymer and respective LCD (limit of detection) and LOQ. (limit of quantification)
[0469] Sample partially hydrolyzed poly (N-vinylformamide) Degree of Unlabeled LCD LOG r2 Fiused as educt FITC labelpolymer [PPm] [PPm] gure ling per polspiked
[0470] ymer [mol% [wt%]
[0471] of labeling in
[0472] the labeled
[0473] polymer]
[0474] Sample Theoretical Degree of
[0475] MW [g / mol] hydrolysis [%]
[0476] L1 E1 550000 50 0.0054 0 0.097 0.29 0.99 7A L2 E1 550000 50 0.0027 0 0.12 0.37 0.99 7A L3 E1 550000 50 0.00054 0 0.18 0.56 0.99 7A L4 E1 550000 50 0.000054 0 1.54 4.67 0.75 7A L1* E1 550000 50 0.0054 0 0.04 0.13 0.99 7B L5 E1 550000 50 0.0054 10 0.04 0.13 0.99 7B L6 E1 550000 50 0.0054 50 0.07 0.21 0.99 7B L7 E1 550000 50 0.0054 90 0.05 0.15 0.99 7B L8 E1 550000 50 0.0054 99 0.15 0.46 0.99 7B L9 E2 550000 95 0.11 0 0.06 0.19 0.99 7C L10 E2 550000 95 0.11 10 0.06 0.19 0.99 7C L11 E2 550000 95 0.11 50 0.06 0.18 0.99 7C L12 E2 550000 95 0.11 90 0.05 0.16 0.99 7C
[0477]
[0478] L13 E2 550000 95 0.11 99 0.06 0.19 0.99 7C
[0479] Analysis of successful coupling of FITC to polyamines
[0480] The proof of covalent bonding of the labelling reagent was demonstrated e.g. for example L1 through the absence of free labelling reagent or its hydrolysis product. This was done directly using HPLC on the labeled polymer (sample preparation: 400 mg of the polymer solution are weighed into a 25 ml volumetric flask, dissolved in 2 ml of DMSO, mixed with 1 ml of 25% ammonia solution (for analysis, supplier Bernd Kraft) as a derivatization reagent, and thenthe flask is filled with ammonium carbonate buffer for HPLC, containing 30-33% ammonia base, supplier Fluka. To this solution, 0.25 g of BaCI2 (>99%, supplier Honeywell / Fluka) is added to precipitate the polymer matrix. An aliquot of 5 l of the filtered (0.2 pm filter) solution is injected onto the HPLC column; column: Xselect CSH Phenyl-Hexyl 5 pm 150x4,6 mm, supplier Waters; column temperature 35°C, pressure 120 bar, flow 1 ml / min, run time 38 min, mobile phase A: 1 ,3g / l ammonium carbonate pH 8.2, mobile phase B methanol; solvent gradient A / B (% / %) 80 / 20 -0 / 100 in 20 min; 0 / 100 - 80 / 20 in 5 min; detection: 494 nm) Alternatively free dye was quantified indirectly through dialysis through PES membrane with a cut-off of 10 kDa (Amicon® Ultra, Merck KGaA, Darmstadt, Germany) and quantification of the fluorescence signal in the permeate. No fluorescence was found in the permeate samples.
[0481] Example 8 Detection and quantification limits of partially hydrolysed N(vinylformamides) labeled with FITC and respective corresponding unlabeled partially hydrolysed N(vinylformamides):
[0482] Quantification of unlabeled polymers, like of partially hydrolysed N(vinylformamides) or pDADMAC, in a cell culture matrix can be performed by e.g. 2D-HPLC or size exclusion chromatography:
[0483] Quantification of the flocculation agents pDADMAC and a partially hydrolysed N(vinylformamide) with a theoretical MW of 550000 g / mol and a degree of hydrolysis of 50% (E1) was performed using a two-dimensional high-performance liquid chromatography (2D-HPLC) method coupled with charged aerosol detection (CAD).
[0484] Samples were prepared by pipetting 100 pL of the antibody sample into HPLC vials, followed by dilution with 400 pL of 0.1% trifluoroacetic acid (TFA) in deionized water (Milli-Q grade), yielding a 1:5 dilution. The mixture was vortexed for 30 s, sonicated for 2 min, and centrifuged at 2,000 ref for 1 min at room temperature. For recovery validation, spike-in samples were prepared by adding 100 pL of a 200 mg / L flocculant standard solution to 100 pL of the sample, followed by 300 pL of 0.1 % TFA in water.
[0485] The first chromatographic dimension employed a semi-preparative reversed-phase HPLC system (Thermo Scientific Ultimate 3000) equipped with a MAbPac RP column (100 x 3.0 mm, 4 pm; Thermo, PN: 088644) maintained at 45 °C. A binary gradient was applied using mobile phase A (0.1% TFA in H2O) and mobile phase B (0.1% TFA in acetonitrile), with a flow rate of 0.6 mL / min and an injection volume of 100 pL fractions containing flocculants (elution window: 10.8-13.5 min) were collected in 1.5 mL HPLC vials.
[0486] Collected fractions were dried in a vacuum centrifuge (SpeedVac, Eppendorf Concentrator Plus) at room temperature for ~5 h and reconstituted in 40 pL of 0.1% TFA in water. After vortexing and centrifugation (2,000 ref, 1 min), the entire volume was transferred to fresh HPLC vials for analysis.The second dimension utilized an analytical inverse HPLC system (Thermo Vanquish) with a ProSwift RP-4H column (50 x 1.0 mm; Thermo, PN: 069477) at 55 °C. A binary gradient was applied using mobile phase A (0.1% heptafluorobutyric acid (HFBA) in H2O) and mobile phase B (0.1% HFBA in 80% acetonitrile / 20% 2-propanol). The flow rate was 0.3 mL / min with a 10 pL injection volume. Detection was performed using a charged aerosol detector (Thermo Vanquish CAD VH-D20-A) at 90 °C, with a data acquisition rate of 10 Hz, filter time of 3.6 s, and power setting of 2.00 under analytical gas regulation mode.
[0487] Calibration was performed using external standards of pDADMAC (Merck, Darmstadt, Germany) and of the partially hydrolysed N(vinylformamide) with a theoretical MW of 550000 g / mol and a degree of hydrolysis of 50% (E1) in the range of 10-200 ppm. Three independent stock solutions were prepared and used to generate calibration curves via polynomial regression (second order). Calibration solutions were vortexed and centrifuged prior to injection. Peak areas were plotted against known concentrations, and the resulting regression equations were used to calculate analyte concentrations in unknown samples. The method's limit of detection (LCD) and limit of quantification (LOQ) were 10 ppm and 20 ppm for pDADMAC, and 20 ppm and 30 ppm for the partially hydrolysed N(vinylformamide) with a theoretical MW of 550000 g / mol and a degree of hydrolysis of 50% (E1), respectively.
[0488] Method precision was assessed using replicate analyses (n=5) of a 200 ppm flocculant solution, yielding a relative standard deviation (RSD) of <3.0%. Accuracy was evaluated through spike-in recovery experiments and was found to be influenced by matrix effects, which were mitigated through the use of recovery controls and matrix-matched calibration.
[0489] Although Khodadadian et al. (Biologies 57, 21(2019)) reported that size exclusion chromatography coupled with evaporitic light scattering detector was able to detect pDADMAC in monoclonal antibody formulations or during downstream quantification to a quantification limit (LOQ) or 0.85 ppm and a detection limit (LCD) of 0.26 ppm in sample matrix, the used methodology is complexand strong protein-pDADNMAC interactions can negatively affect sensitivity and accuracy of the measurements. So, there is a simple, quick and selective in situ method for quantification of residual partially hydrolysed N(vinylformamide) with LOQ and LOD below 1 ppm is needed.
[0490] Polymer stocks of labeled partially hydrolyzed poly (N-vinylamide) according to formula V or of a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV were diluted to concentrations in the range between 0.1 to 5 ppm using purified water using at least 4 points. Dilutions were prepared in duplicates. 200 L dilution per well of a 96 well plate was measured with a Spark® multimode plate reader (Tecan Trading AG, Switzerland) with an excitation wavelength of 485 nm (bandwidth: 20 nm) and an emission wavelength of 535 nm (bandwidth: 20 nm) at room temperature. All dilutions of a labeled partially hydrolyzed poly (N-vinylamide) according to formula V were measured in one plate at room temperature at optimal gain and the blank was subtracted. The same principle was used for respective mixtures of a partiallyhydrolyzed poly (N-vinylamide) according to formula I and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV. Adapted from validation guideline ICH Q2(R1 ), LOD and LOQ were estimated based on a up to 5 point- calibration curve between 5 - 0.1 ppm by LOD = 3.3cr I m and LOQ = 10a I m with cr being the standard error of the y-intercept and m being the slope of the curve (Table 5, Figure 7).
[0491] In general, fluorescence intensity increased with increasing degree of labeling in linear manner. Irrespective of base polymer a labeling of 0.00054 mol% and higher in the labeled polymer allow detection and quantification of the residual polymer in the low ppb range. A labeling of 0.000054 mol% in the labeled polymer led to weak correlation and LOD as well as LOQ in the low ppm range indicating insufficient traceability in the ppb range due to insufficient fluorescence intensity.
[0492] Mixtures of labeled and unlabeled polymer yielded the same LOD and LOQ with r2 > 0.99 indicating lacking matrix effects on fluorescence in presence of unlabeled polymer (Figure 7: B and C).
[0493] Example 9 Synthesis of partially hydrolyzed poly (N-vinylamides) labeled with of Bodipy-lsothiocyanat (4,4-D iflu ro-8-(4-isothiocy an atopheny I)- 1 , 3,5, 7-tetramethy l-2,6-diethy l-4-bora-3a, 4a-diaza-5-indacene) according to formula IV or V (R3 = CS-bodipy with bodipy = 8-(4-aminophenyl)-4,4-difluro-1 ,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-5-indacene) (L14; 0.00056 mol % of OS bodipy as label in the labeled polymer)
[0494] To a stirred solution of 120 g partially hydrolyzed poly (N-vinylformamide), degree of hydrolysis 50%, MW approx. 550000 g / mol, solid content 18% (E1), adjusted to pH 11 by addition of 10% sodium hydroxide solution, 0.9502g of a 0.05% solution of Bodipy-lsothiocyanat (4,4-Difluro-8-(4-isothiocyanatophenyl)-1 ,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-5-indacene) in dimethyl sulfoxide was added and the mixture was stirred for 1h at ambient temperature. The pH was adjusted to 7.5 by addition of 30% hydrochloric acid solution. A clear, light-yellow solution, solid content 17,8%, was obtained and used without further purification.
[0495] The so obtained stock was diluted to concentrations in the range between 0.1 to 5 ppm using purified water using 4 points. Dilutions were prepared in duplicates. 200 piL dilution per well of a 96 well plate was measured with a Spark® multimode plate reader (Tecan Trading AG, Switzerland) with an excitation wavelength of 501 nm (bandwidth: 20 nm) and an emission wavelength of 547 nm (bandwidth: 20 nm) at room temperature at optimal gain and the blank was subtracted. In analogy to the above described method LOD and LOQ were estimated based on the 4 point- calibration
[0496] Example 10 Impact of labeled partially hydrolyzed poly (N-vinylamides) on the flocculation performance in cell culture.
[0497] To determine the effect of labelling on flocculation, L1 (an FITC labeled partially hydrolyzed poly (N-vinylformamide) with a FITC labelling of 0.054 mol% of labeling in the labeled polymer and prepared from a partially hydrolyzed poly(N-viny Iformamide with a theoretical MW of 55000 g / mol and a degree of hydrolysis of 50%) was compared to the unlabeled educt (a partially hydrolyzed poly (N-vinylformamide with a theoretical MW of 55000 g / mol and a degree of hydrolysis of 50%; E1) and the non-flocculated control. Cells were harvested at a cell viability of approximately 55-85% (n = 3). Each cell culture was flocculated with 555 ppm of the respective above mentioned labeled or non-la-beled partially hydrolyzed poly (N-vinylformamide) (calculated on the pure polymer, excluding salt content; corresponding to 1000 ppm solid content including salts) and incubated for 20 min. All obtained mixtures were centrifuged at 100 g for 10 min.
[0498] General procedure for the preparation of respective cell cultures:
[0499] As mammalian host cell lines, a CHO-S producing Trastuzumab cell line, or a CHO-GS producing Anti-Spike cell line (developed by Icosagen AS (Tallinn, Estonia)), or a CHO-K1 producing cNISTmAb cell line (National Institute of Standards and Technology (NIST) (Research Grade Test Material 10197)) were used.
[0500] Cryovials of 1 mL with 107cells / mL were stored in the vapor phase of liquid nitrogen and thawed at room temperature. After thawing, 10 mL of freshly prepared basal medium was added, and cells were centrifuged at 200 g for 5 min at 20°C. The supernatant was discarded, and cells were resuspended in 25 mL of fresh basal medium. Cell cultures were grown at 37°C, 8% CO2, 120 rpm in a CO2 incubator shaker New Brunswick S41 i with 2.5 cm orbit (Ep-pendorf, Hamburg, Germany; Art.Nr.: S411230011) and maintained between a cell count of 0.5 and 4x106cells / mL (passaged every 3 or 4 days). Cell viability and cell count were measured using Vi-CELL XR Cell Counter (Beckmann Coulter, Brea, USA, Art.Nr.: 383556). Cell Counter was supplied with Trypan Blue (Merck, Darmstadt, Germany, Art.Nr.: T8154-100ML) to allow cell staining and determination of cell viability. On the day of inoculation, cells were centrifuged at 200 g for 5 min at 20°C and were resuspended in 10% spent media and 90% fresh media at a seeding cell density of 7.5 x 105cells / mL. The fed-batch experiments for Trastuzumab and cNISTmAb were carried out either in a 500 mL disposable vented Erlenmeyer shake flasks (Art.Nr.: 734-1887, starting volume 150 mL) or 1000 mL disposable vented Erlenmeyer shake flasks (Art.Nr.: 734-1889, starting volume 400 mL). Anti-Spike cultures were cultivated in 1800 mL DASGIP Bioblock system (Eppendorf, Hamburg, Germany; 76DG04CCBB, starting volume 1000 mL). The DASGIP bioblock system consisted of a glass bioreactor (Eppendorf, Hamburg, Germany; 76SR1500CDLS) with a 3-Blade Impeller, 30° pitch (Art.Nr.: 78532236).
[0501] In the bioreactors, the cultivation conditions were set to a constant pH of 6.9 ± 0.05, a constant dissolved oxygen rate (DO) of 40 % and a stirrer speed starting at 80 rpm gradually increasing to 250 rpm over the course of 9 days to maintain the DO (VisiFerm DO EOS 325 DO probe; Hamilton, Reno, USA; Art. Nr. :234666-241 ). The pH was controlled by CO2 addition in the sparger gas flow as acid and the addition of 7.5 % sodium bicarbonate as base. The DO was controlled by the proportion of oxygen in the sparger gas flow and the gas flow. Antifoam C Emulsion (Sigma Aldrich, Darmstadt, Germany; Art.Nr.: A8011) was added dropwise on demand to control foam levels. Feeding of cells was performed by daily addition of HyClone™ Cell Boost™ 7a (Cytiva, Uppsala, Sweden) at 2% of the batch volume and HyClone™ Cell Boost™ 7b (Cytiva, Uppsala, Sweden) at 0.2% of the batch volume starting from day 3on. On day 5 of the fed-batch cultivation the temperature was reduced from 37°C to 32°C. Viability and cell count were measured daily and the harvest criteria was a drop of viability below 70%. The so obtained cell cultures were used in the Examples.
[0502] The flocculation in the examples below were performed at pH 6 with mammalian cell cultures producing respective antibodies after stopping the cultivation (= harvest) at a cell viability between 55-85%, unless stated otherwise. The performance in flocculation was characterized by antibody yield and / or DNA removal and / or host cell protein (HOP) removal and / or turbidity and / or residual polymer:
[0503] (In the following the term "cultivation supernatant” is used for a sample which is obtained from a mammalian cell culture after stopping the cultivation, adding a flocculant followed by centrifugation and separating the supernatant; in case of the non-flocculated controls the step of adding a flocculant is not carried out).
[0504] Antibody concentration was determined by analytical protein A chromatography on a Dionex Ulti Mate 3000 HPLC system (Thermo Fisher Scientific, Waltham, USA) with Chromeleon™ 7 software (Thermo Fisher Scientific, Waltham, USA). The system was set to a flow rate of 2.5 mL / min. The cultivation supernatant was filtered over a filter with 0.22 pm pore diameter and 50 pl of the resulting filtrate was loaded on a POROS A 20-pm column (2.1 x 30 mm), 0.1 ml column volume (Thermo Fisher Scientific, Waltham, USA, Art. Nr.: 2100100). The column was equilibrated with 10 column volumes of mobile phase A consisting of 50 mM phosphate buffer with 150 mM NaCI pH 7.0, eluted with a step gradient with 20 column volumes of 100% 100 mM mobile phase B consisting of glycine buffer, pH 2.5, and re-equilibrated with 30 column volumes of mobile phase A. The absorbance at 280 nm was used for antibody quantification. A protein A chromatography purified lgG1 was used as calibration standard (expected retention time: 0.9 min).
[0505] DNA was detected and quantified using the Quant-IT PicoGreen dsDNA assay Kit (Thermo Fisher Scientific, Waltham; USA; Art.Nr.: P7589).
[0506] HOP quantification: First, the cultivation supernatant was pre-treated using cation exchange chromatography in batch mode to avoid interactions of residual flocculant with the HOP ELISA Kit to be used in the determination. Therefore, 50 pl cultivation supernatant was diluted with 4 pl of a 4 mol / L sodium chloride solution (the so obtained mixture has a concentration of 300 mmol / L NaCI). Afterwards, 10 pL of a 50% slurry of cation exchange resin, which was obtained by resuspending, decanting and diluting the resin ESHMUNO CP-FT suspension (Merck, Darmstadt, Germany; Art.Nr.: 1200930010) in 50 mM phosphate buffer pH 5.5, was added. The obtained mixture was incubated for 1 hour at 22°C at 800 rpm using Thermomix comfort 5355 (Eppendorf, Hamburg, Germany). After centrifugation the supernatant was separated and the HCP content in the supernatant was quantified using the CHO HCP ELISA Kit, 3G (F550-1) (Cygnus Technologies, Southport, USA; Art.Nr.: F550-1).Turbidity in Nephelometric Turbidity Unit (NTU) was determined with 9 ml of cultivation supernatant by a 2100Q Portable Turbidimeter (Hach, Loveland, USA).
[0507] Residual polymer concentration of fluorescence labeled partially hydrolysed poly (N-vinylformid) was determined by measuring the fluorescence using a Tecan Spark plate reader (Tecan Trading AG, Mannedorf, Switzerland). The excitation wavelength was 475 nm and emission wavelength was 520 nm. To correct background signal, RO-H2O (RO = reverse osmose) as well as non-flocculated cell culture supernatant were used as blanks. All samples, standards and blanks were measured at least in duplicates in a sample volume of 200 piL in a black 96-well-plate (Thermo Fisher Scientific, Waltham, USA). Quantification was based on a 4-point calibration curve from 1-25 ppm using fluorescently labeled polymer diluted in RO-H2O.
[0508] Cell cultures of Trastuzumab, Anti-Spike and cNISTmAb reached an antibody titer of 1.0, 0.7 and 2.3 g / L at a cell density between 14-24'106 cells / mL. After harvesting, addition of the above-mentioned respective flocculants reduced turbidity below 15 NTU, DNA by more than 99% and HCPs up to 45% without impacting antibody yield within all tested models compared to respective non-flocculated controls (Figure 8). Clarification was equal when using L1 and the corresponding non-labeled partially hydrolyzed poly (n-vinylformamid) (having a theoreticl MW of 550000 and a degree of hydrolysis of 50%) (E1) indicating no negative effect of label on performance.
[0509] Overall, the performance of the labeled polymer was comparable to the unlabeled polymer. After flocculation and centrifugation only 4.3 ± 0.9 ppm in the Trastuzumab case, 6.2 ± 0.6 ppm in the Anti-Spike and 6.0 ± 0.7 ppm in the cNISTmAb case of labeled polymer were found in the supernatant. (These ppm values are calculated on the theoretical solid content including salts).
[0510] Example 11 Impact and traceability of labeled partially hydrolyzed poly (N-vinylamides) during Downstream purification
[0511] To showcase the traceability in platform purification trains and compatibility with standard chromatography resins of the labeled partially hydrolyzed poly (N-vinylamides) a process showcase was performed with Anti-Spike.
[0512] Cell culture of Anti-Spike from Example 10 was flocculated with 555 ppm of L9 (an FITC labeled partially hydrolyzed poly (N-vinylformamide) with a FITC labelling of 0.11 mol% of labeling in the labeled polymer and prepared from a partially hydrolyzed poly (N-vinylformamide) with a theoretical MW of 55000 g / mol and a degree of hydrolysis of 95% (calculated on the pure polymer, excluding salt content; corresponding to 1000 ppm solid content including salts) (E2)) as described in Example 10. After centrifugation the supernatant was purified using a downstream purification consisting of protein A chromatography followed by cation exchange chromatography (CEX). All chromatographic steps were conducted with a chromatographic workstation AKTA Avant 25 coupled with a fraction collector (Cytiva, Uppsala, Sweden). Protein A affinity chromatography was performed on MabSelect PrismA resin (Cytiva), customprepacked in a 0.8x10 cm OPUS Mini-Chrom column. The equilibration and elution buffer were 1x PBS at pH 7.4 and 25 mM citrate buffer at pH 3.2, respectively. The eluate was collected using the fractionating system and was neutralized and simultaneously preconditioned by 1:2 dilution using CEX equilibration buffer (50 mM acetate at pH 5.5). CEX resin Capto S ImpAct (Cytiva) was custom prepacked in a 0.8x5 cm OPUS MiniChrom housing (Repligen, Waltham, USA). The elution buffer was 50 mM acetate + 1000 mM sodium chloride at pH 5.5. Residual L9 was determined for each fraction as described in Example 10.
[0513] For all chromatographic steps no impact of the labeled partially hydrolyzed poly (N-vinylformamide L9 on separation efficacy was observed. The residual labeled partially hydrolyzed poly (N-vinylformamide L9 content in the load was 10.2 ppm. Around 7.6 ppm residual labeled partially hydrolyzed poly (N-vinylformamide L9 was removed in Protein A flowthrough showing a tremendous reduction of the polymer. The labeled partially hydrolyzed poly (N-vinylformamide L9 was not traceable in protein A wash and elution or CEX flowthrough, wash and elution. (These ppm values are calculated on the theoretical solid content including salts)
[0514] Example 12 Flocculation of a recombinant E. coli lysate
[0515] A recombinant E. coli strain was cultivated in mineral salt media in high-cell density fed-batch fermentation. After fermentation, cells were rebuffered in water or 100 mM TRIS-HCL buffer pH 8 and pH adjusted before cell lysis via high-pressure homogenization. The lysate was pH-adjusted to pH 5-7 depending on experiment and flocculated with 1,000 - 5,000 ppm (solid content including salts) of the respective partially hydrolyzed poly (N-vinylformamide) of formula I.
[0516] The optimal concentration of the respective partially hydrolyzed poly (N-vinylformamide) of formula I was determined using an analytical centrifuge (LUMIsizer® (LUM GmbH, Berlin, Germany) based on sedimentation velocity. The measurement cell was placed into the instrument and exposed to centrifugal force under 4,000 rpm rotor speed at 25 °C at 870 nm. A total of 450 profiles were recorded in intervals of 2 sec. For evaluation the so-called method "Position der Phasengrenze” (Position of the phase boundary”) was used. Sedimentation velocity was positively influenced by the concentration of the partially hydrolyzed poly (N-vinylformamide) of formula I. Sedimentation velocity for pDADMAC increased from roughly 130 pim / s (1,000 ppm pDADMAC) over 830 pim / s (2,500 ppm pDADMAC) to 960 pim / s (5,000 ppm pDADMAC) at pH 7. For partially hydrolyzed poly (N-vinylformamide) X9 a similar pattern was observable with less than 100 pim / s (1,000 ppm as well as 2,500 ppm partially hydrolyzed poly (N-vinylformamide) X9 based on solid content including salts; corresponding to 555 ppm and 1,388 ppm calculated on the pure polymer, excluding salt content) to 800 pim / s (5,000 ppm partially hydrolyzed poly (N-vinylformamide) X9 based on solid content including salts; corresponding to 2,775 ppm calculated on the pure polymer, excluding salt content). Interestingly 2,775 ppm partially hydrolyzed poly (N-vinylformamide) X9 (calculated on the pure polymer, excluding salt content; corresponding to 5,000 ppm solid content including salts) led to comparable sedimentation velocities like 2,500 ppm pDADMAC. Sedimentation velocity for partially hydrolyzed poly (N-vinylformamide) X9 was not affected by lysate pH.Based on sedimentation velocities, only samples flocculated with 2,500 ppm and 5,000 ppm (based on solid content including salts) were used for further analysis of the supernatant. Supernatant was obtained by centrifugation of flocculated sample at 13,000 g for 10 min. Residual dsDNA was detected using the Quant IT™ PicoGreen® dsDNA Assay Kit (Thermo Fisher Scientific, P7589). A Host Cell Protein (HCP) ELISA was employed to quantify residual host cell proteins, using the Biogenes E. coll 360-HCP ELISA Kit targeted for E. coll W3110 (a K12 wildtype strain). The Pierce™ Chromogenic Endotoxin Quant Kit was used to measure residual lipopolysaccharide (LPS) levels through a chromogenic Limulus amebocyte lysate (LAL) based reaction. In general, partially hydrolyzed poly (N-vinylforma-mide) X9 was as effective as pDADMAC (pH 7) in reducing DNA by more than 97% and endotoxins by more than 99% at equal pure polymer concentrations (Figure 9). Partially hydrolyzed poly (N-vinylformamide) X9 led to reduced residual HCP levels at equal pure polymer concentrations compared to pDADMAC at pH 7. While for DNA and LPS removal media pH had no influence on removal efficiency, lower pH seemed more favorable for HCP removal, see Figure 9.
[0517] Example 13 Flocculation of a recombinant E. coll lysate
[0518] A recombinant E. coll strain was cultivated in mineral salt media in high-cell density fed-batch fermentation. After fermentation, cells were rebuffered in water or 100 mM TRIS-HCL buffer pH 8.0 and pH adjusted appropriately before cell lysis via high-pressure homogenization. After flocculation at pH 6 of 300 g E. coll lysate with 2,775 ppm partially hydrolyzed poly (N-vinylformamide) X9 (calculated on the pure polymer, excluding salt content; corresponding to 5,000 ppm solid content including salts) or 5,000 ppm pDADMAC, filter aid Harborlite 800 (Thermofisher, Darmstadt, Germany) at 3 wt% was added and subsequent pressure filtration. Pressure filtration was achieved using lab-scale pressure filter equipped with filter medium PP1001 SK54 (Sefar GmbH, Edling, Germany) with a filter area of 20 cm2filter area at 0.4 bar overpressure.
[0519] Material flocculated with partially hydrolyzed poly (N-vinylformamide) X9 led to good filtration properties with a homogeneous solid filter cake with a filter resistance of 9.70x1012mPas / m2while material flocculated with pDADMAC led to slow and incomplete filtration with a liquid filter cake and a filter resistance of 1.11x1015mPas / m2. Clarification was measured as transmission at 600 nm using a UV spectrophotometer (Mettler Toledo, GieBen, Germany). The respective filtrates indicated improved clarification for partially hydrolyzed poly (N-vinylformamide) X9 with 81% transmission compared to 23% transmission for pDADMAC.
Claims
Claims1. A method for purifying an antibody or fragment thereof from an antibody secreting cell culture, comprising at least the following steps:a) treating the cell culture with(I) a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof:nNR^formula Iwherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl;(II) a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof:formula IV,wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; or(iii) a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof:formula V,wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label;andb) separating the cell culture into a precipitate / solid and a supernatant / liquid fraction.
2. The method according to claim 1, wherein the partially hydrolyzed poly (N-vinylamide), or salt thereof, comprises at most 90 mol-% of monomer units according to formula IIR2formula" andat least 10 mol-% of monomer units according to formula III:NRXHformula IIIwherein R2 = H or C1-C4 alkyl; preferably R2 = H, CH3 or C2H5 and wherein Rx= H, CH3, or C2H5; preferably Rx= H.
3. The method according to claim 2, wherein the partially hydrolyzed poly (N-vinylamide) used in step a) i) or step a) ii) comprises 80 to 4 mol-% of monomer units according to formula II and 20 to 96 mol-% of monomer units according to formula III; preferably wherein the poly (N-vinylamide) comprises 80 to 20 mol-% of monomer units according to formula II and 20 to 80 mol-% of monomer units according to formula III.
4. The method according to any of claims 1 or 2, wherein the partially hydrolyzed poly (N-vinylamide) used in step a)i) or step a)ii) exhibits a degree of hydrolysis of at least 20 mol-%, preferably of at least 25 mol-%, more preferably of at least 30 mol-%.
5. The method according to any of the preceding claims, wherein the labeled partly hydrolyzed poly (N-vinylamide) according to formula IV used in step a)ii), or wherein the labeled partly hydrolyzed poly (N-vinylamide) according to formula V used in step a) iii) comprises 80 to 4 mol-% of monomer units according to formula II and 20 to 96 mol-% of monomer units according to formula III; preferably wherein the labeled partly hydrolyzed poly (N-vinylamide) comprises 80 to 20 mol-% of monomer units according to formula II and 20 to 80 mol-% of monomer units according to formula III.
6. The method according to any of the preceding claims wherein the labeled partially hydrolyzed poly (N-vinyla-mide) according to formula IV used in step a) ii) or wherein the labeled partly hydrolyzed poly (N-vinylamide) accordingto formula V used in step a) ill) exhibits a degree of hydrolysis of at least 20 mol-%, preferably of at least 25 mol-%, more preferably of at least 30 mol-%.
7. The method according to any of the preceding claims wherein in the mixture of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV used in step a) II) the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV are present in a wt% ratio of 99:1 to 1:99.
8. The method according to any of the preceding claims, wherein the degree of hydrolysis is determined by ion charge density measurements using polyelectrolyte titration, determination of the amount of acid obtained due to the hydrolysis such as formic acid, enzymatic based tools; near infrared spectroscopy, or NMR spectroscopy.
9. The method according to any of the preceding claims, wherein the partially hydrolyzed poly (N-vinylamide) used in step a)i) or in step a)ii), or the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV used in step a) ii), or the labeled partially hydrolyzed poly (N-vinylamide) according to formula V used in step a)iii) has a K-value between 10 and 250, preferably between 15 and 200.
10. The method according to any of the preceding claims, wherein separating in step b) comprises a solid-liquid separation step selected from filtration, centrifugation, sedimentation, decantation; preferably filtration, more preferably in depth filtration.
11. The method according to any of the preceding claims, wherein the supernatant is subjected to one or more of the following further purification steps: chromatography such as anion-exchange chromatography, cation-exchange chromatography, hydrophobic-interaction chromatography, affinity chromatography ; filtration such as micro-filtration, ultrafiltration; crystallization, precipitation for example by using ammonium sulfate and extraction for example by using multiphase systems.
12. The method according to any of the preceding claims, wherein the antibody secreting cell culture is a mammalian cell culture; preferably a cell culture comprising Chinese ovary hamster (CHO) cells.
13. The method according to any of the preceding claims, wherein the antibody or fragment thereof is a monoclonal antibody; preferably wherein the monoclonal antibody is a humanized monoclonal antibody or a human monoclonal antibody, more preferably, wherein the monoclonal antibody is selected from the group consisting of Trastuzumab, Anti-Spike, Adalimumab, cNSITmab.
14. The method according to any of the preceding claims as described in step a)i), wherein the step of treating the cell culture with the partially hydrolyzed poly (N-vinylamide) according to formula I comprises adding a sufficient amountof said partially hydrolyzed poly (N-vinyl amide) according to formula I, in particular at least 50 ppm; more particularly adding at least 100 ppm, still more particularly at least 300 ppm, even more particularly at least 500 ppm of said partially hydrolyzed poly (N-vinylamide) to the cell culture,orthe method according to any of the preceding claims as described in step a)ii), wherein the step of treating the cell culture with the mixture of the partially hydrolyzed poly (N-vinylamide) according to formula I and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV comprises adding a sufficient amount of said mixture of partially hydrolyzed poly (N-vinyl amide) according to formula I and labeled partially hydrolyzed poly (N-vinylamide) according to formula IV, in particular at least 50 ppm; more particularly adding at least 100 ppm, still more particularly at least 300 ppm, even more particularly at least 500 ppm of said mixture of partially hydrolyzed poly (N-vinylamide) according to formula I and labeled partially hydrolyzed poly (N-vinylamide) according to formula IV to the cell culture;orthe method according to any of the preceding claims as described in step a)iii), wherein the step of treating the cell culture with the labeled partially hydrolyzed poly (N-vinylamide) according to formula V comprises adding a sufficient amount of said labeled partially hydrolyzed poly (N-vinyl amide) according to formula V, in particular at least 50 ppm; more particularly adding at least 100 ppm, still more particularly at least 300 ppm, even more particularly at least 500 ppm of said labeled partially hydrolyzed poly (N-vinylamide) according to formula V to the cell culture.
15. An antibody or fragment thereof obtained by or obtainable by the method according to any of the preceding claims.
16. A composition comprising the antibody according to claim 15.
17. The composition according to the two preceding claims, wherein the composition comprises at most 5%, preferably at most 2 % of residual DNA and / or low levels of one or more of the following host cell proteins (HCPs): 78 kDA glucose regulated protein (GRP78, BiP), Clusterin, Cathepsin B, procollagen-lysin2-oxoglutarate 5-deoxygenaose 1 (PLOD1).
18. Use of a partially hydrolyzed poly (N-vinylamide) according to formula I or salt thereof, a mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof and a labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereof, or a labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereof for antibody purification,wherein formula I isnNR^formula Iwherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl, wherein the sum of R1 = H, COR2 is 100%.;wherein formula IV isformula IV,wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; and wherein the sum of R1 = H, COR2 and R3 is 100%;wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0,00001 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; and wherein the sum of R1 = H, COR2 and R3 is 100%.
19. A labeled partially hydrolyzed poly (N-vinylamide) according to formula IV or a salt thereofformula IV,wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00005 mol % of the monomer units R1 = R3 = a label, in particular a fluorescent label; in particular as described in any of the preceding claims;ora labeled partially hydrolyzed poly (N-vinylamide) according to formula V or a salt thereofformula V,wherein n is an integer in the range of 50 to 150000, Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units in R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and in at least 0.00001 mol % of the monomer units R1 = R3 = a label; in particular a fluorescent label; in particular as described in any of the preceding claims;ora mixture of a partially hydrolyzed poly (N-vinylamide) according to formula I or a salt thereof:formula Iwherein n is an integer in the range of 50 to 150000, wherein Rx= H, CH3, or C2H5; wherein in at least 10 mol-% of monomer units R1 = H and in at most 90 mol-% of monomer units R1 = COR2; wherein R2 = H or C1-C4 alkyl; and the labeled partially hydrolyzed poly (N-vinylamide) according to formula IV, in particular as described in any of the preceding claims.
